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 1 
Zusammenfassung 
LeuO ist ein konservierter LysR-Typ Transkriptionsregulator (LTTR) in Escherichia coli und anderen 
Gammaproteobakterien. LeuO reguliert Gene, die unter anderem für Pathogenität und 
Stressantworten verantwortlich sind. Viele der LeuO-regulierten Gene werden durch das globale 
Repressorprotein H-NS reprimiert und co-reguliert. Daher wird LeuO als globaler Antagonist von H-
NS angesehen. LTTRs regulieren ihre Zielgene typischerweise als Tetramere, die sich aus zwei 
Dimeren der N-terminalen DNA-Bindungsdomänen (DBDs) und zwei Dimeren der C-terminalen 
Effektorbindungsdomänen (EBDs) zusammensetzen. Viele der bisher beschriebenen LTTRs benötigen 
einen Effektor, der strukturelle Veränderungen induziert. Diese strukturellen Veränderungen führen 
zur Änderung der DNA-Bindung des LTTR und ermöglichen die Aktivierung oder Repression 
spezifischer Zielgene. Die Regulation der LeuO Aktivität und deren strukturelle Merkmale sind jedoch 
weitgehend unbekannt. 
In dieser Arbeit wurde der CRISPR-assoziierte cas Promotor als ideales Reporter identifiziert, da er 
sensitiv Veränderungen der LeuO-Aktivität abbildet. Mit diesem Reporter wurden in einem 
genetischen Screen neun hyperaktive Mutanten von LeuO identifiziert, welche den Reporter bei 
basaler Expression voll aktivieren. Die gelösten Kristallstrukturen der EBDs des wild-typischen LeuO 
und der hyperaktiven Ser120Asp Mutante zeigen, dass die Mutationen, die Hyperaktivität bewirken, 
in der Dimerisierungsoberfläche der EBD lokalisiert sind. Eine Überlagerung der Strukturen der EBDs 
deutet darauf hin, dass die S120D-Mutation eine strukturelle Veränderung induziert, welche einen 
Effektor-gebundenen Zustand nachahmt. Diese strukturelle Veränderung kann sich dann auf die 
sterische Anordnung der DBDs übertragen und somit die DNA-Bindeeigenschaften beeinflussen. Eine 
DNase I Footprint Analyse der LeuO-Bindestellen in der Region des cas Promotors zeigt eine 
hochspezifische DNA-Bindung der LeuO Mutante (S120D), welche außerdem im Vergleich zum wild-
typischen LeuO ein deutlicheres Bindemuster an die DNA zeigt. Eine detaillierte Analyse dieses 
Bindemusters deckte eine "Core-Site" auf, welche im Weiteren die Definition eines palindromischen 
DNA-Bindemotifs ermöglichte. Die Daten deuten darauf hin, dass LeuO möglicherweise eine andere 
Gruppe von Zielgenen reguliert, wenn ein Effektor gebunden ist, der strukturelle Veränderungen des 
Proteins auslöst. Die Analyse von hyperaktiven Mutanten, welche vermutlich eine Effektor-
gebundene Form abbilden, kann zum Verständnis des molekularen Mechanismus der 
Transkriptionsregulation durch LeuO beitragen. 
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Abstract 
LeuO is a conserved LysR-type transcriptional regulator (LTTR) of global function in Escherichia coli 
and other Gammaproteobacteria. LeuO regulates genes related to pathogenicity and stress 
adaptation, many of which are co-regulated by the nucleoid-associated global repressor protein H-
NS. Therefore, LeuO is considered a general H-NS antagonist. LTTRs typically are tetramers that 
consist of two dimeric N-terminal DNA-binding domains (DBDs) and two dimeric C-terminal effector-
binding domains (EBDs). Many LTTRs described so far require an effector which induces structural 
changes that lead to alteration of the LTTR activity in repression or activation of specific target genes. 
However, the regulation of LeuO activity and its structural features are poorly understood. 
In this work, I characterized the CRISPR-associated cas promoter as the most sensitive reporter for 
monitoring LeuO activity. Using this reporter nine LeuO mutants were identified in a genetic screen 
that render LeuO hyperactive. The solved crystal structures of the EBDs of wild-type LeuO and one of 
the hyperactive mutants (Serine 120 to aspartic acid exchange) revealed that all mutations causing 
hyperactivity localize to the dimerization interface of the EBD. Comparison and superposing of the 
structures of the wild-type and S120D EBDs suggests that the mutation of S120D induces a structural 
change that mimics an effector-bound state. This structural change is presumed to transmit to the 
arrangement of the DBDs and changes the binding to the DNA. DNase I footprinting of the cas 
promoter region presented here revealed a highly specific DNA-binding and a more distinct DNA-
binding pattern of the S120D mutant compared to the wild-type LeuO. A detailed analysis of these 
footprints unraveled a “core-site” of palindromic sequence, which allowed the definition of a specific 
DNA-binding sequence motif for LeuO. The data indicate that LeuO might regulate a different set of 
target genes when an effector is bound. This is relevant in understanding the molecular mechanism 
of transcriptional regulation by LeuO and the role of LeuO as a global regulator. 
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1 Introduction 
Bacteria face harsh and quickly changing environmental conditions encountering various stresses and 
changing nutrition sources. In order to adapt to, and survive in different environments, bacteria like 
E. coli have evolved a complex gene regulation network (Lee et al., 2012). The regulation of 
transcription by transcription factors allows an individual control of a single gene or of specific 
subsets of genes in response to an environmental stimulus. Activating transcription factors bind close 
to the transcription start site and orchestrate the formation of the transcription initiation complex. 
These activators can directly recruit the RNA polymerase to the promoter or they induce structural 
changes of the DNA promoter region, enabling the binding and initiation of transcription by RNA 
polymerase (Browning & Busby, 2016). Most repressive transcription factors inhibit transcription 
initiation by steric hindrance, in which the repressor DNA-binding denies access of the RNA 
polymerase to the promoter. A repressor can also block transcription initiation by targeting the 
activating transcription factor. Contrary, a transcriptional factor can also obstruct a potential 
repressor and hence indirectly activate transcription (Browning & Busby, 2016). 
The family of LysR-type transcriptional regulators (LTTRs) is most prevalent in bacteria. The LysR-type 
transcriptional regulators activate or repress diverse sets of genes related to virulence, stress 
responses and motility (Maddocks & Oyston, 2008). The activity of LTTRs is controlled by an effector 
that binds to an “effector-binding cleft” or elsewhere, or by modification of amino acids. LeuO is a 
conserved LysR-type transcription regulator in Enterobacteriaceae regulating many targets related to 
stress adaptation, pathogenicity and biofilm formation (Henikoff et al., 1988, Dillon et al., 2012, 
Guadarrama et al., 2014b). However, the control of LeuO activity and the mechanism of its regulation 
have not been studied in detail. For LeuO, no effector or condition is known that modulates its 
activity. Further, the intrinsic structural properties of LeuO and its DNA-binding mode are open 
questions. In this work, a functional and structural analysis of the LysR-type transcription regulator 
LeuO was conducted.  
 
1.1 LysR-type transcription regulators 
LysR-type transcription regulators (LTTRs) represent the largest family of transcription factors, 
resembling 16% of the overall repertoire of transcription factors in bacteria (Tropel & van der Meer, 
2004). They are highly conserved and orthologues have been identified in Archaea and eukaryotic 
organisms (Henikoff et al., 1988, Schell, 1993, Maddocks & Oyston, 2008). To date, 46 LTTRs are 
present in Escherichia coli K12 (Karp et al., 2014) and these LTTRs are involved in the regulation of 
diverse cellular functions as oxidative stress responses, metabolic pathways, virulence and biofilm 
formation (Laishram & Gowrishankar, 2007, Maddocks & Oyston, 2008, Liu et al., 2011). Many LysR-
Introduction 
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type-regulators are homo-tetramers and their activity is controlled by structural changes within the 
tetrameric structure. These structural changes can be induced by effectors or the modification of 
amino acid residues. Effectors can bind to a specific “binding pocket”, in the interface of two dimers 
or elsewhere on the tetramer. Different effectors that bind to the LTTR can regulate different target 
loci or even change the LTTR from an activator to a repressor at a given target loci (Laishram & 
Gowrishankar, 2007). In general, LTTRs regulate expression of a target gene by binding two distinct 
sites in the promoter region matching the degenerated consensus binding motif T-11N-A (Maddocks 
& Oyston, 2008). 
 
1.2 Structure of LysR-type transcription regulators (LTTRs) 
LTTR monomers comprises of approximately 300 amino acids. They consist of a characteristic N-
terminal DNA-binding domain (DBD) with a winged helix-turn-helix (wHTH) domain that connects via 
a helical linker and a flexible hinge to a C-terminal effector-binding domain (EBD, also called 
regulatory domain, RD; Figure 1)(Maddocks & Oyston, 2008, Momany & Neidle, 2012) The DNA-
binding domain is highly conserved and the wHTH domain comprises of three core helices, forming a 
helical bundle with an almost triangular outline. The specific DNA target is determined by the α3 
DNA-recognition helix and forms a DNA-protein interface by insertion into the major groove of the 
DNA (Aravind et al., 2005). The “wing” is a β-strand hairpin unit between helix α3 and α4 and usually 
interacts with the minor groove of the DNA (Aravind et al., 2005). Two DBDs can dimerize via their α4 
helical linker and bind to a palindromic DNA sequence in an inverted arrangement of the DBDs. 
The homology of the C-terminal effector-binding domain (EBD) in LTTRs is less well conserved on the 
amino acid sequence level, but the EBDs have a conserved domain structure. The EBDs exhibit a 
typical fold with two / subdomains (also called RD-1 and RD-2 domains) that connect by two 
extended, antiparallel cross-over β-strands. A cleft locates between the two subdomains of the EBD 
(RD-1 and RD-2) and for some LTTRs effectors are described to bind in this cleft. Two EBDs dimerize 
in antiparallel head-to-tail orientation and form a conserved dimerization interface (Figure 2). In this 
dimerization interface, likewise effector-binding was described (Jiang et al., 2018). 
Several structures of LTTRs are solved so far, and a typical LTTR tetramer can be described as a dimer 
of dimers, where a dimer comprises of two monomers, dimerizing via their EBDs and displaying an 
extended and a compact conformation of their DBDs, as shown by the structure of a structure model 
of LeuO in Figure 2. The assembly of the tetramer arises when the compact DBD subunits interact 
with the extended DBD subunits of the other EBD dimer and contact is made by their linker helices 
(Henikoff et al., 1988, Maddocks & Oyston, 2008, Momany & Neidle, 2012, Taylor et al., 2012).  
Introduction 
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Figure 1: The domain structure of a monomeric LysR-type regulator. 
LTTR monomers consist of an N-terminal winged HTH DNA-binding domain (DBD) connected via a helical linker 
and a hinge to a C-terminal effector-binding domain (EBD). The DNA recognition helix is shown in red. The α4 
helical linker, depicted in yellow is important for dimerization of the DBDs. A “cleft” exists between the two 
regulatory subdomains (RD-1 and RD-2) where a putative effector binds or the modification of an amino acid 
residue may alter the protein structure. However, alternative effector-binding sites exist for some LTTRs in the 
interface of two EBD. Depicted is the monomeric structure of LeuO as example of a LysR-type transcriptional 
regulator (uniprot entry: P10151; https://swissmodel.expasy.org/repository/uniprot/P10151). The figure was 
adapted from (Lerche et al., 2016) and generated using PyMOL (The PyMOL Molecular Graphics System). 
 
The tetrameric LTTR harbors two dimers of the DBD that bind to two adjacent imperfect palindromic 
sites of the DNA, a high affinity DNA binding site (generally called RBS, regulatory binding site) and an 
alternative low-affinity DNA-binding site (ABS, activator binding site) (Toledano et al., 1994, Wek & 
Hatfield, 1988, Rhee et al., 1998). For most LTTRs, this target recognition and binding to the DNA is 
independent of a bound effector. However, the binding of an effector or the mutation of an amino 
acid residue can induce structural changes of the EBDs and subsequently change the distance or the 
angle of the two DBDs, as shown for OxyR (Figure 2D) (Jo et al., 2015). This steric re-arrangement 
alters the DNA-binding pattern, the DBD dimer bound to the high affinity DNA-binding site is 
maintained, while the second DBD dimer “slides” along the DNA to an alternative DNA-binding site. 
This “sliding” along the sequence, leads to a different DNA-binding pattern, resulting in a differential 
regulation of gene expression. LTTRs regulate transcription of target genes by this “sliding-dimer”-
mechanism, as described for example for DntR (Lerche et al., 2016, Toledano et al., 1994). The 
mechanism of the sliding dimer was also shown by DNase I footprinting for BenM, ArgP and OxyR 
(Bundy et al., 2002, Laishram & Gowrishankar, 2007, Kullik et al., 1995). 
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6 
 
Figure 2: Predicted tetrameric structure of LeuO. 
A top view (A) and a side view (B) of the predicted LeuO tetramer structure with monomeric LeuO proteins 
highlighted in blue, grey, green and magenta (uniprot entry: P10151; 
https://swissmodel.expasy.org/repository/uniprot/P10151 based on (Lunin et al., 2005)). Dimerization is 
shown of the effector-binding domains EBD-1 (blue) with EBD-2 (grey) and dimerization of EBD-3 (green) with 
EBD-4 (magenta). The DNA-binding domain DBD-1 dimerizes with DBD-4 and the DBD-2 dimerizes with DBD-3. 
The α3 DNA-recognition helices are marked in orange. (C) A structural model of the DBD-dimer. The individual 
monomers of the DBDs are depicted in grey and green with the α3 DNA-recognition helices marked in orange. 
The dimerization of the DBDs is mediated by the α4 linker helices. (D) The reduced (left side) and oxidized form 
of OxyR (right side) shows the structural change transmitted to the DBDs upon oxidization of the protein (Jo et 
al., 2015). The α3 helices of the DBDs are indicated by number and the distance between DBD-1 and DBD-3 is 
120 Å in the reduced full-length protein. The DBD-1/DBD-2 dimer and the DBD-3/DBD-4 dimer should get closer 
by 45 Å during the transition to the oxidized state (Jo et al., 2015). The figure was generated using PyMOL (The 
PyMOL Molecular Graphics System). 
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1.3 Regulation of target genes by LysR-type regulators 
Structural changes in the LTTR tetramer can be induced by binding of an effector or a modification of 
an amino acid residue. The LTTR BenM in Acinetobacter sp. controls the aromatic compound 
metabolism by regulating genes in the β-ketoadipate pathway (Bundy et al., 2002). In absence of an 
effector, BenM binds to the promoter of benA (encoding a benzoate-dioxygenase) and represses 
transcription. In the presence of the metabolites benzoate and muconate structural changes of BenM 
shift the binding to a different DNA-binding site of the benA promoter region and BenM 
synergistically activates the transcription of benA expression. In this way, the benzoate degradation is 
directly coupled to the presence of benzoate in the cell (Bundy et al., 2002). 
Modifications of an amino acid are possibly caused by a change of pH or by oxidation. An example for 
the control of an LTTR by amino acid modification is the hydroxylation of the cysteine residue (C199) 
in OxyR, leading to structural changes of the tetrameric OxyR. Consequently, the OxyR-regulated 
small RNA oxyS is activated which regulates the oxidative stress response (Toledano et al., 1994, Jo et 
al., 2015, Kullik et al., 1995). The OxyR-C199D mutant described in (Jo et al., 2015) mimics an 
oxidized form of the protein that renders the protein active. For AphB in Vibrio cholera the N100E 
mutation renders the pH-sensitive transcription regulator active at non-permissive pH 8.5. The 
structures of wild-type AphB and of mutant N100E revealed structural changes of the tetrameric 
AphB that render AphB-N100E constitutively active at its target loci (Taylor et al., 2012). Mutations in 
the EBD of LysR-type regulators can render the LTTR constitutively active, suggesting that the 
mutation mimics an effector-bound state and induce the same structural change as the effector. 
Constitutively active mutants were also described for the LTTRs AmpR, CysB, DarR, NahR, TsaR, and 
XapR (Balcewich et al., 2010, Colyer & Kredich, 1994, Jones et al., 2018, Schell et al., 1990, Monferrer 
et al., 2010, Jørgensen & Dandanell, 1999). 
Effectors are usually metabolites or ions and can bind either to the cleft between the two RD 
subdomains of the EBD or to a secondary binding site in the dimeric interface of two EBDs (Jiang et 
al., 2018). In some cases, different effectors are bound by the LTTR. 
These effectors can alter the transcription regulation of the LTTR as a direct read out of a stimulus in 
the cell. For example, to prevent toxic levels of arginine in the cell, the LTTR ArgP binds the effector 
arginine and activates the transcription of the arginine exporter encoding argO. When lysine is bound 
to ArgP transcription of argO is inhibited and also additional ArgP target genes are inhibited 
(Laishram & Gowrishankar, 2007). The LTTR NdhR coordinates the balance of carbon and nitrogen 
metabolism in cyanobacteria. For NdhR two effector binding sites were identified, where different 
effectors can bind (Jiang et al., 2018). One binding site is located in the cleft of the effector-binding 
domain between two RD subdomains and binds 2-PG (2-phosphoglycolate, depicted in green; Figure 
Introduction 
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3). A secondary binding site is located in the dimeric interface of two EBDs of NdhR and binds 2-OG 
(2-oxoglutarate, shown in blue; Figure 3). Binding of either one of the effectors to different sites of 
the protein allows a fine-tuning in the regulation, depending on the incoming signal. NdhR adopts a 
repressor conformation upon 2-OG binding. The binding of 2-PG to the cleft induces structural 
changes and leads to the activation of gene expression. When the repressing effector is bound, the 
activating effector is no longer able to bind due to the structural changes (Jiang et al., 2018). 
It is noteworthy that some of the described LTTRs map next to genes they regulate, linking their 
location to their function. For example, BenM regulates the transcription of the divergent benA gene 
(Maddocks & Oyston, 2008, Bundy et al., 2002). In the E. coli genome about 50% of the LTTRs map 
divergently to their target genes. The LTTR IlvY is located divergent to its regulated target gene ilvC 
(Wek & Hatfield, 1988). The ilvC gene encodes a ketol-acid reductoisomerase for branched-chain 
amino acid synthesis (Rhee et al., 1998).  
 
 
Figure 3: The binding of effectors to different sites of the LTTR NdhR. 
Depicted is dimer of the NdhR tetrameric structure with two different effectors (indicated in green and blue) 
bound to different sites in the structure (Jiang et al., 2018). The effector 2-PG (in green) binds to the cleft 
between the two RD subdomains of NdhR and induces gene expression. The effector 2-OG (in blue) binds to a 
secondary binding site in the dimer interface between two EBDs and acts as co-repressor of NdhR (Jiang et al., 
2018). 
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1.4 LeuO 
LeuO is a pleiotropic LysR-type transcriptional regulator and conserved in Gammaproteobacteria 
(Henikoff et al., 1988, Hernández-Lucas & Calva, 2012, The UniProt Consortium, 2017). LeuO has 
been best studied in the species Escherichia coli and Salmonella enterica, as well as in Vibrio cholera. 
The LeuO proteins are 90% identical in the Enterobacteriaceae and 50% identical to LeuO in V. 
cholera and LeuO is presumed to act as a tetramer, like other LTTRs (Guadarrama et al., 2014b). 
LeuO regulates more than 100 loci in E. coli and S. enterica, as identified by microarray transcriptome 
analyses and genomic SELEX screening (Dillon et al., 2012, Shimada et al., 2011, Stratmann et al., 
2012, Ishihama et al., 2016). LeuO activates and represses loci related to acid-stress resistance, 
pathogenicity, multi-drug efflux, and biofilm formation (Henikoff et al., 1988, Dillon et al., 2012, 
Guadarrama et al., 2014b). 
Among many targets, LeuO activates the transcription of CRISPR-cas bacterial defense system, 
important for defense against foreign DNA and phage infection (Medina-Aparicio et al., 2011, Pul et 
al., 2010, Westra et al., 2012, Hernández-Lucas & Calva, 2012). Further, LeuO plays a positive role in 
the regulation of the yjjQ-bglJ operon, encoding FixJ/NarL-type transcriptional regulators and the bgl 
operon, encoding proteins for uptake and utilization of aryl-β,D-glucosides (Ueguchi et al., 1998, 
Stratmann et al., 2008). In Vibrio, LeuO inhibits the expression of the cholera toxin (CT) and the toxin 
co-regulated pilus (TCP). Furthermore, leuO expression is activated by the membrane bound 
transcription regulator ToxR, which links leuO expression to various stimuli that activate the ToxR-
dependent virulence regulon of V. cholerae (Ayala et al., 2018, Bina et al., 2013, Ante et al., 2015a, 
Ante et al., 2015b). 
Many LeuO-activated target loci, like the CRISPR-cas operon, are repressed by the global repressor H-
NS (heat-stable nucleoid structuring protein) and its paralogue StpA. LeuO presumably competes 
with H-NS for DNA-binding and delimits spreading and thus the formation of the repressing 
oligomeric H-NS complex (De la Cruz et al., 2007, Chen & Wu, 2005, Westra et al., 2010). LeuO is 
therefore considered an H-NS antagonist (Ueguchi et al., 1998, De la Cruz et al., 2007). However, in 
several pathways LeuO has been identified as additional repressor of H-NS-repressed gene loci and 
thus seems to functionally cooperate with H-NS or functions as a “back-up” of H-NS. For example, 
LeuO causes repression via HilE of pathogenicity island 1 (SPI-1) in Salmonella when repression by H-
NS is impaired (Espinosa & Casadesús, 2014).  
The leuO gene (GenBank Accession number U00096.3 K12: 84,368 to 85,312) is located between the 
divergent leuLABCD operon and the ilvIH operon, both encoding enzymes for the synthesis of 
branched-chain amino acids (Gemmill et al., 1983, Wang & Calvo, 1993) (Figure 4). In standard 
laboratory conditions leuO is silent, but is moderately induced in response to starvation in stationary 
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growth phase (Majumder et al., 2001, Fang et al., 2000). Transcription of leuO is repressed by H-NS 
and StpA under standard laboratory conditions (Klauck et al., 1997, Stratmann et al., 2012). 
Transcription of leuO is activated by the transcription regulator BglJ-RcsB and by the LysR-type 
regulator LrhA (Stratmann et al., 2012, Breddermann & Schnetz, 2017). LeuO itself shows a weak 
positive autoregulation, when expressed in high copy numbers (Chen & Wu, 2005). However, LeuO 
acts as a negative autoregulator, counteracting the activation by BglJ-RcsB as well as by LrhA, and 
derepression in hns stpA mutants (Stratmann et al., 2012, Breddermann & Schnetz, 2017). Two 
distinct LeuO DNA-binding sites in the promoter sequence of leuO have been described (Stratmann 
et al., 2012).  
Although LeuO regulates many target loci, only a degenerated consensus DNA-binding motif was 
identified displaying the typical weak LysR-type binding motif T-11N-A (Dillon et al., 2012, Maddocks 
& Oyston, 2008). The weak DNA-binding specificity might be increased when LeuO activity is altered 
by an effector or an amino acid modification, as described for other LysR-type regulators. Up to date, 
no effector or condition has been described that modulates the LeuO activity. 
 
 
Figure 4: Schematic model of the organization of the leuO promoter region including the binding sites of 
transcriptional regulators. 
The leuO gene is located between the operons ilvIH and leuLABCD, both encoding for enzymes involved in 
branched-chain amino acid synthesis. LeuO DNA-binding sites are indicated as black boxes, the H-NS 
nucleation site is shown as red box and the binding site for the heterodimeric activator BglJ-RcsB as grey box 
(Stratmann et al., 2012). Transcription of leuO is repressed by H-NS and StpA under standard laboratory 
conditions. The promoter P2 is activated by BglJ-RcsB, while LrhA mainly activates P3 (and weakly P and P1). In 
hns stpA mutant strains, LeuO acts as an autorepressor, and it counteracts the activation by LrhA and BglJ-
RcsB in the wild-type (Stratmann et al., 2012, Breddermann & Schnetz, 2017). 
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1.5 Objectives of this thesis 
LeuO is a pleiotropic LysR-type regulator modulating the transcription of many target loci in 
Escherichia coli. For other LysR-type regulators effectors or modifications of amino acids have been 
described which alter the activity of the protein. No effector is known so far for LeuO and the control 
of LeuO activity is poorly understood. Additionally, the mode of LeuO binding to the DNA and the 
mechanism of regulation of its target loci remain open questions. 
In this study, I identified the cas promoter as the most sensitive reporter for analyzing the activity of 
LeuO. Using this reporter, I isolated nine LeuO mutants that are highly active causing full activation 
even when present at low levels. I further characterize the LeuO structure, by crystallization of the 
effector-binding domains (EBDs) of the wild-type LeuO and one of the hyperactive mutants (S120D). 
The structures revealed that all hyperactive LeuO mutants map in the dimerization interface of the 
EBDs and the S120D mutant causes a structural change.  
In addition, I determined the DNA-binding mode of wild-type LeuO, of the hyperactive LeuO-S120D 
mutant and of the LeuO-DBD dimer. The DNA-binding specificity of the S120D mutant and of the DBD 
dimer is higher than of wild-type LeuO, which enabled the identification of a palindromic DNA-
binding sequence and a specific LeuO DNA-binding motif. Furthermore, using the motif I identified 
and initiated the characterization of putative LeuO target loci. 
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2 Results  
2.1 Screen for hyperactive LeuO mutants 
For the LysR-type regulator LeuO no effector is known, while for other LysR-type regulators, such as 
AphB, XapR and OxyR, effectors have been described and amino acid mutations have been 
characterized that render these regulators constitutively active (Taylor et al., 2012, Jørgensen & 
Dandanell, 1999, Jo et al., 2015). Therefore, to characterize LeuO, I set up a screen for LeuO mutants 
that are constitutively active. As a reporter, the promoter of the cas (CRISPR-associated) operon, 
which is activated by LeuO (Pul et al., 2010, Westra et al., 2010) was fused to lacZ, and this Pcas-lacZ 
fusion was integrated into the genome (at the phage λ attachment site attB) in a ΔlacZ ΔleuO Δ(yjjP-
yjjQ-bglJ) background (T1610; Figure 5A). The expression of the Pcas-lacZ reporter was strongly 
activated by LeuO (from 6 units to 568 units), when LeuO was expressed at high levels using a 
plasmid carrying leuO under the control of the IPTG (isopropyl-β,D-thiogalactopyranoside) inducible 
tac promoter (Figure: 5B and 5C), as shown before (Westra et al., 2010). At basal expression levels of 
LeuO, without induction of Ptac, LeuO activated Pcas-lacZ moderately (compare 51 units to 6 units of 
control, Figure 5B). Thus, the basal expression level of LeuO is a suitable condition to screen for 
constitutive LeuO mutants. In this screen, promoter lacZ fusions of the LeuO-activated bgl and yjjQ 
promoters were also included as reporters (Schubert, 2013). However the Pcas-lacZ fusion was found 
to be the most sensitive reporter. For mutagenesis the leuO gene fragment was amplified by PCR in 
parallel reactions, using the non-proofreading Taq polymerase, and the PCR fragments were ligated 
into the Ptac expression plasmid (Figure 5A). Transformants of the Pcas-lacZ reporter strain with 
these ligations were screened for a Lac-positive phenotype on tryptone X-Gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside) indicator plates without IPTG (Figure 5A and 5C). Nine different 
mutations of single amino acid residues were isolated from 25 independent mutagenesis PCR 
reactions. These mutants include 3 independent isolates of LeuO-S128P as well as 2 independent 
isolates each of LeuO-H142R, LeuO-Q210R, LeuO-A237V and LeuO-H254R, respectively. The mutants 
LeuO-T127I and LeuO-R218C, respectively, were isolated once. The mutant LeuO-M244T was isolated 
as a single mutant and as an independent double mutant with the second mutation V230I (Figure 
8A). In addition, mutant LeuO-S120D was isolated as a triple mutant with additional amino acid 
exchanges at residues E111D and D205N. This triple mutant was isolated using the Pbgl-lacZ reporter 
strain (Schubert, 2013) (Figure 8A). To analyze the impact of LeuO Ser120 to Asp exchange, a single 
mutant was constructed and used for further analysis. Multiple independent isolations of the same 
mutants suggest that the screen for constitutively active LeuO mutants was saturated. 
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Figure 5: Screen for constitutively active LeuO mutants. 
(A) To screen for active LeuO mutants, a Pcas-lacZ fusion was integrated into the chromosomal attB-site of 
strain T1281 [ΔlacZ ΔleuO Δ(yjjP-yjjQ-bglJ)], and this Pcas-lacZ fusion was used as reporter for LeuO activity 
(top left side). The leuO gene was amplified by non-proofreading PCR and the leuO fragments were ligated 
into plasmid pKESK22 (carrying a p15A replication origin, kanamycin resistance) to place leuO under control of 
the IPTG inducible tac promoter (Ptac) (top right side). Transformants were selected on tryptone X-Gal, 
kanamycin indicator plates and screened for a Lac-positive phenotype (A bottom). Of a total of 17 Lac
+ 
clones 
the leuO fragment was sequenced, which revealed 9 different leuO mutants (see Table 3). (B) Activation of 
Pcas by LeuO mutants. Expression levels of Pcas-lacZ were determined of cultures grown without induction 
(top panel) and with 1 mM IPTG for induction of leuO expression (bottom panel). Expression was determined 
in absence (vector control, pKESK22) and in presence of plasmid-provided LeuO (pKETS5) and its mutants 
S120D (pKESL104), T127I (pKESL74), S128P (pKESL75), H142R (pKESL76), Q210R (pKESL77), R218C (pKESL78), 
A237V (pKESL80), M244T (pKESL73), and H254R (pKESL101). Cultures for β-galactosidase assays were 
inoculated from overnight cultures and grown in LB medium with kanamycin to an OD600 of 0.5. Where 
indicated 1 mM IPTG was added both to the overnight and exponential culture. Mean values of at least 3 
independent biological replicates are shown as bars, and error bars indicate standard deviations. (C and D) 
Spotting of Pcas-lacZ strain (T1281) carrying leuO on a plasmid. Over day cultures were grown in LB with 
antibiotics to an OD600 ~ 3.0 and diluted to OD600 = 1.0 for spotting. OD600 = 1.0 equals approximately 10
9
 cells 
per ml, and 10 µl (= 10
-2
 ml) and 10 µl of the ten-fold serial dilutions (10
-3
, 10
-4
, 10
-5
, 10
-6
, 10
-7
, 10
-8
) 
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The LeuO mutants conferring a Lac+ phenotype at basal expression levels (without IPTG) were used in 
a quantitative assay of Pcas-lacZ activation (Figure 5B). To this end, transformants of the Pcas-lacZ 
reporter strain with plasmids carrying leuO mutants were grown without (no IPTG) and with 
induction of leuO expression (1 mM IPTG) and the β-galactosidase activities were determined. When 
LeuO expression was induced (1 mM IPTG), all mutants caused full activation of Pcas-lacZ (Figure 5B, 
bottom panel). At basal expression levels of leuO, without induction, all LeuO mutants isolated in the 
screen fully activated the Pcas-lacZ reporter (Figure 5B top panel). The expression levels ranged from 
362 to 708 units referring to a 7 to 14-fold stronger activation of Pcas-lacZ than by wild-type LeuO 
(51 units, Figure 5B top panel). Thus, each of the nine mutations of single amino acid residues render 
LeuO hyperactive. Interestingly, all the residues locate in the effector-binding domain (EBD, amino 
acid residue 108 to 314), and not a single mutant mapped to the N-terminal DNA-binding domain 
(DBD, amino acid residue 1 to 101). 
To visualize the increased activity of LeuO-S120D and to further analyze the growth of the mutant, 
transformants of the Pcas-lacZ reporter strain (T1281) with plasmids expressing wild-type (pKETS5, 
p15A-ori or pKESMS38, pBR-ori) and mutant LeuO (pKESL104, p15A-ori or pKESMS79, pBR-ori) were 
spotted in serial dilutions on tryptone X-Gal indicator plates with and without 200 µM IPTG. Empty 
plasmids served as control (pKESK22, p15A-ori or pKES334, pBR-ori). The plasmids carrying ap15A-ori 
express moderate levels of LeuO (Figure 5C), while pBR-derived plasmids express high levels of LeuO 
(Figure 5D), under the control of the IPTG inducible tac promoter. Transformants were grown in LB 
with antibiotics to an OD600~3.0 and diluted to OD600=1.0 (equals approximately 10
9 cells per ml). 
Ten-fold serial dilutions were made and 10 µl was pipetted per spot of each dilution (= 10-2, 10-3, 10-4, 
10-5, 10-6, 10-7, 10-8 per ml). 
The Pcas-lacZ strain expressing LeuO showed a blue phenotype when induced with IPTG and a light 
blue color when the plasmids were not induced. In agreement with the data from β-galactosidase 
assays, the mutant LeuO-S120D conferred a Lac+ phenotype even when no IPTG was present. Further 
the cells expressing wild-type LeuO showed a normal growth (up to dilution 10-8), while the 
hyperactive LeuO-S120D mutant conferred a growth defect when the expression was induced from 
the high-copy number pBR-ori plasmid (no growth as of dilution 10-4). This suggests that high levels of 
Figure 5 continued from the previous page 
were spotted on tryptone X-Gal indicator plates, with ampicillin or kanamycin. Plates were supplemented with 
200 µM IPTG where indicated. The reporter strain T1281 was transformed with plasmids expressing LeuO or 
LeuO-S120D under the control of the IPTG inducible lacI
q
-tac promoter system and either (C) expressed 
moderate levels of LeuO from a low to medium copy plasmid (p15A origin of replication; pKESK22, control; 
pKETS5, LeuO; pKESL104 LeuO-S120D) or (D) high levels of LeuO from a pBR derived plasmid (pKES334, 
control; pKESMS38, LeuO; pKESMS79 LeuO-S120D). 
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hyperactive LeuO-S120D are toxic for E. coli cells. Further, all colonies of the dilution 10-3 and 10-4 
were Lac-. The sequencing of leuO in several of these clones revealed an additional mutation W303*. 
The additional mutation leads to a truncated protein with lost hyperactivity. 
 
2.2 Crystal structure of the LeuO effector-binding domain (EBD) 
The nine mutations causing hyperactivity of LeuO, map in the effector-binding domain (EBD) that 
extends from residue Ala108 to Arg314, according to a structural model of E. coli LeuO 
(https://swissmodel.expasy.org/repository/uniprot/P10151) and an alignment of S. enterica LeuO 
with other LysR-type regulators (Figure 6) (Guadarrama et al., 2014a). To characterize the functional 
relevance of these residues, the crystal structure of the LeuO-EBD was determined in cooperation 
with the Lab of Prof. Dr. Ulrich Baumann, Institute for Biochemistry, Cologne (Figure 7). In addition, 
the structure of the EBD of hyperactive mutant LeuO-S120D was solved in an orthorhombic (space 
group I222) and a monoclinic (space group C2) crystal form (Figure 7A). Most residues are well 
resolved in the electron density maps with the exception of the loop connecting strands β4 and β5 
(residues 151-158 including helix α6; secondary structures are numbered according to the prediction 
for the full-length protein), which has weak electron density in the wild-type and in the monoclinic 
crystal form of the S120D structure, but it could be traced in the orthorhombic S120D crystal form. 
Furthermore, the loop between β5 and β6 residues (R173 to E175) is not resolved in the wild-type 
and monoclinic mutant structures and possesses only weak density in the orthorhombic S120D 
structure.  
The EBD exhibits the typical fold with two / subdomains (also denoted as RD domains) connected 
by two extended, antiparallel cross-over β-strands β6 and β11. DALI and PDB FOLD searches revealed 
the effector domain of DntR of Burckholderia sp. as the structurally most similar protein with known 
structure (PDB ID: 5AE5) (Lerche et al., 2016). 
In all three crystal structures, the EBDs form a dimer (Figure 7A) that is predicted to be stable in 
solution under standard conditions as judged by the PISA server (Krissinel & Henrick, 2007). This 
dimer is similar to those observed in structures of other isolated EBDs as well as in full-length 
structures of LysR-type regulators, e.g. in the structures of AphB (Taylor et al., 2012). As anticipated, 
there is no sign of a tetramer in all three crystal structures presented here, because tetramerization 
requires the α4 linker helix of the DNA-binding domain that is not present in the constructs. 
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Detailed analysis of the crystal structures by Prof. Dr. Baumann revealed the following features: The 
three-dimensional structures of wild-type and S120D mutant are similar, however with some 
important differences (Figure 7D). The root-mean-square (RMS) deviation of all 192 equivalent C 
pairs is about 1.7 Å for the superposition of wild-type and each of the two S120D structures, while 
superposing the latter results in a significantly lower RMS deviation of 1.2 Å. Flexible alignment by 
the RAPIDO web server (Mosca & Schneider, 2008) reduced the RMS deviation to about 0.8 Å for 175 
C pairs, revealing two rigid bodies. The first rigid body essentially consists of -strands 3 and 4 and 
helices 5 and 10. This becomes more apparent when superposing only domains RD-2 (residues 
185 to 285), which results in an RMS deviation of the 101 C pairs of 0.4 Å between wild-type and 
each mutant structure. Superposing in this way the entire structures lead to a good alignment of 
both S120D mutant structures, while the wild-type differs especially in the position of -strands 3 
and 4 as well as helices 5 and 10 of domain RD-1 (Figure 7D). Remarkably, the C atoms of the 
first N-terminally resolved residue (Arg112) have a distance of about 4 Å between wild-type and 
mutant (Figure 7D). Similar but less pronounced differences between inactive and active EBDs have 
been observed previously, e.g. in the structures of DntR (PDB ID: 2y7w, 2y7r) (Devesse et al., 2011). 
Interestingly, the largest deviations of the three structures in the RD-2 domain occur at the “arginine 
elbow” at residue 218, of which a mutation to glutamic acid, cysteine or alanine results in 
hyperactivation. 
 
Figure 6: Domain architecture and secondary structure elements of LeuO and LeuO-S120D. 
(A) Schematic presentation of the LeuO domain and secondary structure, with the N-terminal DNA-binding 
domain (DBD) carrying a wHTH motif, and the C-terminal effector-binding domain (EBD), connected by a hinge 
region. Mutations of residues, which render the protein hyperactive, are shown atop and additional mutations 
are depicted below the scheme. The secondary structure of the solved crystal structures is depicted in a 
schematic representation showing α helices as round filled cylinders, η helices as round unfilled cylinders, β  
sheets as arrows and non-solved areas as white boxes. The secondary structure of the DBD (shown in light 
grey) is based on a structural model (https://swissmodel.expasy.org/repository/uniprot/P10151). 
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Intriguingly, the amino acid whose mutation causes hyperactivity, are surface exposed and all map in 
the putative dimerization interface (Figure 7A). The residues Ser120, Arg218, and Met244 are located 
in the vicinity of the putative effector-binding cleft, which is located in between the two / 
subdomains. Met244 is close to its counterpart of the second monomer (Figure 7C). Arg218 is 
reasonably well defined in the wild-type structure and points towards the interior of the putative 
effector-binding pocket. The mutation of residue Ser120 to Asp induces a reorientation of the side-
chain of Arg218 (Figure 7D) with much weaker electron density. Further, in the wild-type protein 
structure there appears to be a chloride ion bound close to the position in which the carboxylate 
group of Asp120 is located in the S120D mutant (Figure 7C). The assignment of the electron density 
peak as chloride is based on the coordination of the ion, the peak height and a weak anomalous 
signal. The putative chloride ion is coordinated by the backbone amide of Met243, the side-chain 
hydroxyl group of Ser120, and two water molecules. The vicinity is otherwise rather hydrophobic, 
with the side-chains of Pro121, Ala242, Met243 and Val214 lining the pocket (Figure 7E). The 
guanidinium group of Arg218 is about 4.5 Å apart from the putative chloride ion (Figure 7C). 
Taken together, crystallization in cooperation with the Lab of Ulrich Baumann and the analysis of the 
crystal structure by Prof. Dr. Ulrich Baumann suggests the typical fold of the EBD with the two / 
subdomains. The structure is quite similar to LysR-type regulator DntR (Lerche et al., 2016) and the 
structural change between the EBDs of LeuO wild-type and the hyperactive S120D mutant is similar 
to structural changes described for other LysR-type regulators. For LysR-type regulators DntR, AphB 
and BenM, the structural changes are induced by an effector binding to the EBD. In the crystal 
structures of the LeuO-EBD and the hyperactive S120D the side-chain of Arg218 is reoriented at the 
edge of the presumptive effector-binding cleft, hinting to an effector regulating the LeuO activity. 
This putative LeuO effector is also supported by the putative chloride ion binding to the rather 
hydrophobic effector binding pocket. The change in the structure, caused by an effector or a 
hyperactive mutant, may transmit to the DNA-binding domains and alter for example the angle of 
the DNA-binding. 
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Figure 7: Crystal structures of LeuO-EBD and LeuO-S120D-EBD monomer and homodimers by Prof. Dr. Ulrich 
Baumann. 
(A) Cartoon representation of LeuO-S120D-EBD dimer with residues causing hyperactivity when mutated. (B) 
LeuO-EBD monomer shown in gradient coloring (blue, N-terminus; red C-terminus), with secondary structure 
elements labeled. A bound chloride ion is shown in green and activating residues are indicated as sticks. (C) 
Close-up view of dimer LeuO-EBD with bound chloride ion and residues Ser120, Met244 and Arg218 shown as 
sticks. (D) Superposition of LeuO-EBD in green and LeuO-S120D-EBD crystallized in different space groups in 
cyan (I222) and purple (C2) in ribbon representation. The C atoms of residue Arg112 have a distance of about 
4 Å between wild-type and mutant. (E) Dimer of the LeuO-EBD. The monomeric EBD is shown in gray ribbon 
(left), with amino acids Pro121, Leu122, Tyr168, Phe219, Met243 (depicted as sticks) lining the pocket that 
holds the putative chloride ion. The second monomeric EBD is shown in tubes in green, blue, yellow, and 
orange. Residues that render LeuO inactive are indicated as magenta spheres (Pro121, Leu122, Ile125, Tyr168, 
and Leu263). Residues that are neutral when mutated compared to wild-type LeuO are depicted in gray 
spheres (Met243, Phe219, and Cys117). Numbering of residues is according to the full-length protein 
sequence of LeuO. The Figure was prepared using Chimera (Pettersen et al., 2004).  
 
2.3 Characterization of additional LeuO mutants 
Residues Ser120, Arg218 and Met244 map close to the putative effector binding pocket, and are 
involved in intramolecular and intermolecular contacts. To further characterize these residues, they 
were mutated to alanine, and Arg218 was in addition mutated to glutamic acid. Further, a LeuO-
S120D/M244T double mutant was constructed. The LeuO mutants were constructed in plasmid 
pKESK22 as before, carrying leuO under control of the IPTG inducible tac promoter (Ptac), a p15A 
replication origin and a kanamycin resistance. The activity of these LeuO mutants was analyzed using 
the Pcas-lacZ reporter (strain T1281). LeuO mutants S120A and M244A showed a reduced activation 
of Pcas compared to wild-type LeuO at basal expression levels (no IPTG, Figure 8A, top panel). Upon 
induction of their expression (1 mM IPTG) the mutants fully activated Pcas (Figure 8A, bottom panel). 
These results show that the hyperactivity is specific for the Ser120 to Asp and Met244 to Thr amino 
acid exchanges, but not caused by the exchange to alanine (S120A and M244A, Figure 8A). The 
double mutant LeuO-S120D/M244T remained hyperactive, causing full activation of the Pcas (Figure 
8A). Interestingly, mutation of Arg218 to alanine or glutamic acid rendered the protein similarly 
hyperactive as the Arg218 to cysteine mutation, which was isolated in the screen and caused full 
activation of Pcas at basal expression levels (Figure 8A). 
LeuO harbors a cysteine residue at position 119, located in the cleft of the EBD. A second cysteine at 
position 117 is located in the dimer interface of the LeuO-EBDs (Figure 7B and 7E). To test the 
relevance of Cys117 and Cys119 for LeuO activity, these residues were mutated to a serine and 
aspartic acid, respectively. The mutant C119D showed increased activation of Pcas at basal 
expression levels compared to the wild-type (increase from 51 units to 148 units; Figure 8A), and 
caused full activation of Pcas at high expression levels. In contrast the other three mutants C117S, 
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C117D and C119S had a slightly reduced activity even when expressed at high levels (Figure 8A). 
Thus, introduction of the negatively charged aspartic acid at residue 119 enhances LeuO activity, 
which may have a similar effect as the mutation of residue 120 from serine to the negatively charged 
aspartic acid in the hyperactive mutants S120D. 
In the solved LeuO-EBD structure several loops showed a weak electron density, as e.g. between β4 
and β5 (residues Q151 to R158) and between β5 and β6 (residues R173 to E175; Figure 7B and 8C). 
To analyze these unstructured regions, amino acids in these loops (Asn150, Gln151, Asn152, His155, 
Gln156, Arg158, His172, Arg173) and additional positively charged residues His204, Trp226 and 
Lys232, were mutated to alanine and to glutamic acid. The mutants Asn150, Gln151, Asn152, His155, 
Gln156, Arg158, His172, Arg173, His204 showed full activation of Pcas when their expression was 
induced with IPTG, irrespective of being mutated to alanine or glutamic acid (Figure 8A). At basal 
expression levels the LeuO mutants N150E, Q151E, Q156E and H204E showed a slightly increased 
activation (2 to 3-fold) of the reporter compared to wild-type LeuO. The LeuO mutants N150A, 
Q151A, N152A, N152E, H155A, H155E, Q156A, R158A and R158E showed a similar activation at basal 
expression levels as the wild-type (Figure 8A). The activation of Pcas was reduced for LeuO mutants 
W226A and W226E with induction and abolished without induction possibly due to protein instability 
or structural changes. The LeuO mutants K232A and K232E had a slightly reduced activity even when 
expressed at high levels and showed no activation at basal expression levels (Figure 8A). 
In the screen for constitutively active LeuO mutants a triple mutant LeuO-S120D/E111D/D205N and a 
double mutant LeuO-V230I/M244T were isolated. In addition, several double mutants of LeuO 
(S120D/E111D, S120D/C119S, M244A/M34V, M244A/G240V) were isolated in the process of cloning. 
The activation of the Pcas-lacZ by these LeuO mutants was analyzed as well. All LeuO mutant variants 
of S120D showed full activation of Pcas-lacZ with and without induction and irrespectively of the 
second or third additional mutation (LeuO-S120D/E111D/D205N, LeuO-S120D/E111D, LeuO-
S120D/C119S; Figure 8A). LeuO mutant M244A/M34V showed a similar reduced activation of Pcas as 
the single mutant of LeuO-M244A, while the activation by LeuO-M244A/G240V was abolished. The 
additional mutant LeuO-M244T/V230I showed full activation of Pcas-lacZ just as the LeuO-M244T 
single mutant. Taken together, the additional secondary LeuO mutations were rather negligible, as 
the activation does not differ significantly from their corresponding single mutant (Figure 8A). 
In order to further characterize residues in the cleft of the EBD, several additional residues were 
mutated (Figure 6 and 7E). Pro121 was mutated to the negatively charged aspartic acid and Leu122, 
Ile125, Tyr168, Phe219, Met243, and Leu263 to negatively charged glutamic acid. The activity of 
these mutants was analyzed using a low copy number (pSC origin) expression plasmid carrying leuO 
under control of the moderate lacUV5 promoter (Figure 8B). The LeuO mutant L122E was 
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additionally analyzed expressing the mutant from the Ptac, p15A-ori kanR plasmid. Upon induction of 
leuO expression mutants F219E and M243E showed a similar activation of the Pcas-lacZ reporter as 
the wild-type LeuO (Figure 8B, plus IPTG). In contrast, activation of Pcas was strongly decreased for 
LeuO mutants P121D, L122E, I125E, Y168E and L263E (Figure 8B, plus IPTG). Expressing the LeuO 
mutant L122E from a medium copy number plasmid (p15A-ori) does not activate the Pcas-lacZ 
reporter without IPTG and showed reduced activation upon induction, compared to the wild-type 
(Figure 8A). Thus, these mutants are inactive possibly due to a structural change or protein 
instability. 
Taken together, the analysis of additional LeuO mutants revealed that hyperactivity is specific for the 
particular amino acid exchanges S120D and M244T, while the activities of mutants C119D, N150E, 
Q151E, Q156E and H204E are moderately increased. Arg218 may be inhibitory since mutation of this 
residue to alanine, cysteine, or glutamic acid, causes hyperactivity. 
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Figure 8: Characterization of additional LeuO mutants. 
Activation of the Pcas-lacZ by LeuO mutants was determined in reporter strain T1281. Expression levels were 
determined of cultures grown without induction (top panel) or with 1 mM IPTG for induction of leuO 
expression (bottom panel). (A) Pcas-lacZ expression was analyzed of transformants carrying Ptac plasmid for 
directing expression of wild-type LeuO (pKETS5), LeuO-DBD (pKESMS63), as well as mutants S120D (pKESL104), 
S120A (pKESL108), R218C (pKESL78), R218A (pKESL238), R218E (pKESL243), M244T (pKESL73), M244A 
(pKESMS1), S120D/M244T (pKESL107). C117S (pKESMS64), C117D (pKESMS67), C119S (pKESMS65),  
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Figure 8 continued from the previous page 
C119D (pKESMS66), L122E (pKESL106), N150A (pKESL221), N150E (pKESL231), Q151A (pKESL229), Q151E 
(pKESL232), N152A (pKESL222), N152E (pKESL233), H155A (pKESL223), H155E (pKESL234), Q156A (pKESL224), 
Q156E (pKESL241), R158A (pKESL228), R158E (pKESL235), H172A (pKESL225), H172E (pKESL236), R173A 
(pKESL226), R173E (pKESL242), H204A (pKESL230), H204E (pKESL237), W226A (pKESL239), W226E (pKESL240), 
K232A (pKESL227), K232E (pKESL244), S120D/E111D (pKESL71), S120D/E111D/D205N (pKESL72), S120D/C119D 
(pKESL105), M244A/M34V(pKESL110), M244A/G240V(pKESL109), V230I/M244T (pKESL79), empty vector 
pKESK22 served as a control (vector). (B) Pcas-lacZ expression was analyzed in transformants carrying low copy 
plasmids (pSC-ori) with the lacUV5 promoter (PUV5) directing expression of wild-type LeuO (pKESL39), and 
mutants S120D (pKESL102), S120D/E111D (pKESL40) P121D (pKESL69), L122E (pKESL103), L122E/H115Y 
(pKESL68), I125E (pKESL64), I125E/V118I (pKESL65), Y168E (pKESL70), F219E (pKESL67), M243E (pKESL61), and 
L263E (pKESL62). The empty parent vector of these plasmids served as control (vector). Cultures for β-
galactosidase assays were grown to in LB medium with appropriate antibiotics to an OD600 of 0.5. Mean values 
of at least 3 independent biological replicates are shown as bars; error bars indicate standard deviations. (C) 
Mutated amino acid residues of unstructured loops of the LeuO protein. The Figure was created using PyMOL 
(The PyMOL Molecular Graphics System). 
 
2.4 The LeuO DNA-binding domain (DBD) is functional 
The LeuO protein in E. coli is presumably a tetramer, like S. enterica LeuO and other LysR-type 
regulators (Guadarrama et al., 2014a) (predicted structure model from 
https://swissmodel.expasy.org/repository/uniprot/P10151 shown in Figure 2A and 2B). Tetramers of 
LysR-type regulators contain two pairs of dimeric effector binding domains (EBD) and two pairs of 
dimeric DNA-binding domains (DBD; Figure 2A and 2B). Dimerization of the N-terminal DBD is 
mediated by the α4 helical linker (Figure 2), while the EBDs provide an additional dimerization 
interface (Figure 7A and Figure 2). In Figure 2A the four monomeric LeuO proteins are highlighted in 
blue, grey, green and magenta. The EBD-1 (blue) dimerizes with EBD-2 (grey) and the EBD-3 (green) 
dimerizes with EBD-4 (magenta). The tetrameric complex is completed by the dimerization of DBD-1 
with DBD-4 and the dimerization of DBD-2 with DBD-3 (shown in Figure 2B and 2C). The α3 helices 
(marked in orange) are the DNA recognition helices, forming the DNA-protein interface by insertion 
into the major groove of the DNA (Aravind et al., 2005) (Figure 2C). 
The two DBD dimers within one tetramer presumably bind to two adjacent sites on the DNA. 
Therefore a single dimeric DBD may be capable of specifically binding to the DNA as well. To address 
this, I tested whether a LeuO DBD-dimer is sufficient to activate the Pcas-lacZ reporter. The DBD (aa1 
to aa101) was expressed using the Ptac expression plasmid pKESMS63, and the capability of the DBD 
to activate the Pcas-lacZ reporter was analyzed. Upon induction of the DBD expression, full activation 
of Pcas-lacZ was observed (Figure 8A). At basal expression levels of the DBD (no IPTG), Pcas 
activation was 4-fold lower by the DBD than by wild-type LeuO, but still detectable (Figure 8A, 
compare 13 and 51 units). These data show that the DBD alone is sufficient to activate Pcas, 
suggesting specific DNA binding by the presumptive LeuO DBD dimer. 
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2.5 LeuO binds to the promoter regions of cas, yjjQ and leuO 
LeuO is an activator of Pcas and PyjjQ and represses its own promoter (PleuO). DNase I footprinting 
showed two distinct LeuO DNA-binding sites for the promoter regions of cas and leuO and three 
putative LeuO DNA-binding sites for PyjjQ (Westra et al., 2010, Stratmann et al., 2012) (and 
unpublished lab data). The LeuO DNA-binding sites are indicated in the schematic view of the 
promoter regions in Figure 9. To further characterize the kinetics of the LeuO binding to the 
individual DNA-binding sites, I performed electrophoretic mobility shift assays (EMSA). 80 bp DNA 
fragments were amplified by PCR, covering the different possible LeuO DNA-binding sites of the 
promoter regions of Pcas (I and II), PleuO (I and II) and PyjjQ (I, II and III; see schemes in Figure 9). 
C-terminally His-tagged LeuO was purified using the ÄKTA fast protein liquid chromatography (FPLC) 
system. The DNA fragments (20 nM) were incubated with increasing concentrations of LeuO and 
separated by gel electrophoresis on 8% native polyacrylamide gels. 
A distinct band is visible for the DNA fragments when no LeuO protein was added. For the fragment 
of LeuO DNA binding site II of the cas locus the intensity of the band decreases at a LeuO 
concentration of 100 nM and a shift is visible. The band intensity of the shift increases at 250 nM and 
is completely shifted at 500 nM and 1000 nM LeuO (Figure 9A). The DNA fragment of DNA-binding 
site I of the cas locus shows a decrease of the band intensity at 250 nM, and the shift is visible at 
protein concentrations 500 nM and at 1000 nM (Figure 9A). The band intensity of both DNA 
fragments of the DNA-binding sites I and II at the leuO locus decreases at LeuO concentration of 250 
nM and is completely shifted at 500 nM and 1000 nM LeuO (Figure 9B). The promoter region of yjjQ 
contains 3 LeuO DNA-binding sites characterized by DNase I footprinting (unpublished lab data; 
Figure 9C). The independent analysis of the single DNA-binding sites shows an unspecific shift for 
DNA-binding site I, where the band intensity starts to decrease at high protein concentrations of 500 
nM and 1000 nM LeuO. Similarly, for DNA-binding site II the band intensity starts to decrease at 250 
nM and 500 nM and is shifted at 1000 nM LeuO. The intensity of the band of DNA-binding site III is 
highly decreased at 250 nM and shifted at 500 nM and 1000 nM LeuO (Figure 9C). For DNA-binding 
site I and II at the yjjQ locus the band is shifted at rather high protein concentrations indicating a low 
unspecific binding to these sites (Figure 9C). 
Taken together, LeuO binds to two distinct DNA-binding sites at the cas and leuO locus with high 
specificity, as shown before (Westra et al., 2010, Stratmann et al., 2012). LeuO binding at the yjjQ 
locus was shown only for binding site III at high protein concentrations. However, a more specific 
characterization of the DNA-binding sites seems not possible, since the EMSA is not sensitive enough 
to characterize differences in the DNA-binding sites. 
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Figure 9: LeuO binding to DNA-binding sites at the cas, leuO and yjjQ loci. 
Binding of LeuO to DNA-binding sites at cas, leuO and yjjQ loci was tested by electrophoretic mobility shift 
assays (EMSA). A schematic view of the promoter regions of Pcas (A), PleuO (B) and PyjjQ (C) is depicted on 
top of each panel, with the LeuO DNA-binding sites indicated (I, II and III) (Westra et al., 2010, Stratmann et 
al., 2012) (and unpublished lab data). The gel pictures of the EMSAs are depicted below each scheme with the 
DNA-binding sites indicated. The 80 bp DNA fragments were amplified by PCR and 20 nM were incubated 
without protein or with increasing concentrations of LeuO as indicated (0, 100, 250, 500 and 1000 nM). The 
samples were separated on 8% native polyacrylamide gels and stained with ethidium bromide.  
 
2.6 DNase I footprinting by LeuO, LeuO-S120D and the LeuO-DBD 
Two extended AT-rich DNA-binding sites for LeuO at the cas promoter region (LeuO sites I and II) 
have been identified by DNase I footprinting (Westra et al., 2010). In these footprints a rather high 
LeuO concentration was used, which corresponds to high levels of wild-type LeuO that is required for 
activation of Pcas in vivo. In contrast, only low levels of the hyperactive LeuO-S120D are required for 
Pcas activation. Therefore, DNA-binding by S120D may be more specific than by wild-type LeuO. To 
test this, DNA-binding of LeuO and its S120D mutant was analyzed by DNase I footprinting using a 
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broad range of protein concentrations. In addition, to narrow down on the DNA-binding sites, LeuO-
DBD was included in the footprinting analysis. The rational of this was that the full-length protein 
carrying two DBD dimers presumably contacts DNA at two sites and therefore yields an extended 
footprint. The DBD presumably occupies only half of the full-length LeuO DNA-binding site, which 
may allow defining a consensus sequence. 
For footprinting His-tagged LeuO, LeuO-S120D and LeuO-DBD were purified. DNA fragments covering 
the full-length LeuO DNA-binding sites I and II of the cas promoter region, were [32P]-labeled at the 
top and bottom strand, respectively, and used for footprinting analysis (Figure 10). Footprints of DNA 
fragments “a” and “b” covering LeuO site II are shown in Figure 11A and 11B, while the footprints of 
LeuO site I (fragments “c” and “d”) are shown in Figure 11C and 11D. Corresponding to the previously 
described LeuO site II, DNase I protection by all 3 proteins was detected (Figure 11A to D). A 
hypersensitive site maps in the middle of this footprint (black triangle) and therefore two half-sites 
IIa and IIb are labeled in the footprint (IIa & IIb, Figure 11 A and 11B). Strikingly, DNase I protection 
by LeuO mutant S120D occurred already at very low protein concentrations (31 nM), suggesting that 
amino acid exchange S120D causes a higher DNA-binding affinity. This higher DNA-binding affinity is 
reflected by additional protection sites only detected for S120D (Figure 11A, 11C, 11D and 12A). 
Intriguingly, the DBD caused a DNase I protection pattern at low concentrations (31 nM) as well, but 
only at DNA-binding site IIa, while at higher protein concentrations (125 nM) both DNA-binding sites 
were protected (Figure 11B). For wild-type LeuO a footprint was apparent as of a concentration of 
125 nM at both DNA-binding sites, but this footprint is more diffuse, at least at DNA-binding site IIb 
(Figure 11A and 11B). The DNase I footprints by LeuO-S120D and in particular by LeuO-DBD indicate 
that DNA-binding site IIa (in LeuO DNA-binding site II) is a high-affinity DNA-binding site, which is 
called “core site” in the following. This “core site” is palindromic (indicated by inverted arrows and 
bold letters, Figure 11A and 11B). Palindromic sequences are typical for DNA-binding of transcription 
regulators with dimeric DBDs (Browning & Busby, 2016). Thus the palindromic sequence of DNA-
binding site IIa may represent one of the two DNA contact sites of the tetrameric LeuO. For LeuO site 
I (footprints of fragments “c” and “d”) all three proteins protected the DNA from DNase I cleavage, 
confirming previous data (Westra et al., 2010) (Fig footprint C and D). However, no palindromic core 
site is apparent in LeuO DNA-binding site I (Figure 12A). Furthermore, the DNase I footprint of LeuO-
S120D showed an additional hypersensitive site, indicating the binding of at least two tetramers that 
might form a higher order complex (open arrowhead, Figure 11A). 
Taken together, these results confirm the LeuO DNA-binding sites at the cas promoter (Westra et al., 
2010). In addition, hyperactive mutant S120D and the DBD bind with higher affinity to LeuO site II 
than wild-type LeuO, Further, the footprint by S120D and DBD is more distinct, and allowed the 
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identification of the core DNA-binding site in DNA-binding site IIa. The palindromic sequence of the 
core site suggests that this represents a close to ideal DNA-binding site of LeuO. 
 
 
Figure 10: Schematic overview of the cas promoter region and DNA fragments for DNase I footprinting with 
LeuOHis6, LeuO-DBDHis6, and LeuO-S120DHis6. 
Indicated are LeuO DNA-binding sites I and II (black boxes) (Westra et al., 2012), the H-NS nucleation site 
(open box), and the transcription start sites (bent arrows) (Pul et al., 2010). Fragments (“a” to “d”) used for 
DNase I footprinting cover either one or both LeuO DNA-binding sites, as indicated. The fragments were 
generated by PCR using primer pairs of which one primer was 5' [
32
P]-labeled, indicated by an asterisk 
(fragment “a”: oligonucleotides [
32
P]-OA477/OA474, fragment “b”: OA477/[
32
P]-OA475, fragment “c”: [
32
P]-
OA476/OA473, fragment “d”: OA477/[
32
P]-OA473). Fragments “a” and “c” were labeled at the top strand, and 
fragments “b” and “d” were labeled at the bottom strand. The [
32
P]-labeled DNA fragments were incubated 
with increasing protein concentrations of LeuOHis6, LeuO-DBDHis6 and LeuO-S120DHis6, as indicated. 
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Figure 11: DNase I footprinting of the cas promoter region. 
Shown are autoradiograms of DNase I footprints of fragment “a” (A) and fragment “b” (B) covering LeuO site II 
of the cas locus, and of fragment “c” (C) and “d” (D) covering LeuO site I. The [
32
P]-labeled DNA fragments 
were incubated with increasing protein concentrations of LeuOHis6, LeuO-DBDHis6 and LeuO-S120DHis6, as 
indicated. Samples were separated on 6% denaturing polyacrylamide gels. Filled arrowheads indicate DNase I 
hypersensitive sites that were detected for all proteins, open arrowheads indicate hypersensitive sites 
detected for one or two protein variants. LeuO-protected sites are marked by two lines (IIa and IIb), 
representing the two half-sites of LeuO DNA-binding site II. The sequence of the protected DNA region is given 
to the right with the palindromic core sequence (at LeuO site II) indicated in bold and with inverted arrows. 
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Figure 12: Compiled overview of the DNase I footprinting results at the cas locus. 
(A) The sequence of the cas regulatory region with the promoters Pcas and anti-Pcas (bent arrows) and the H-
NS nucleation site is shown (Pul et al., 2010). The areas of protection observed in the DNase I footprints are 
indicated by lines above the sequence for protection of the top strand and underneath the sequence for 
protection of the bottom strand, respectively. Protected areas are marked: LeuOHis6 (solid line), LeuO-DBDHis6 
(dashed line) and LeuO-S120DHis6 (dotted line). The 5' [
32
P]-labeled ends of fragments “a” to “d” are indicated 
by lollipops. The presumptive palindromic DNA-binding core site within DNA-binding site II is shown in bold and 
italic, and marked by inverted arrows. (B) The sequence of the leuO regulatory region with promoters, the H-NS 
nucleation site, and BglJ-RcsB binding site indicated, as described before (Breddermann & Schnetz, 2016). LeuO 
DNA-binding sites I and II, which were characterized by DNase I footprinting (Stratmann et al., 2012), are 
labeled with a black line. The presumptive palindromic DNA-binding core site within LeuO DNA-binding site I is 
shown in bold and italics, and marked by inverted arrows. 
 
2.7 DNA-binding consensus sequence of LeuO 
For LeuO, a 28 bp large and rather weak consensus sequence was described before (Dillon et al., 
2012). The DNase I footprint at the cas promoter region revealed the high affinity core DNA-binding 
site IIa harboring a 19 bp palindromic sequence (shown in bold letters and indicated by arrows in 
Figure 11A and 11B and Figure 12A). In the DNA-binding site I of LeuO at the autoregulated leuO 
promoter (Stratmann et al., 2012), an almost identical palindromic sequence was detected within 
LeuO DNA-binding site I at the leuO locus (Figure 12B). The 33 bp sequences covering the palindromic 
sequences of LeuO DNA-binding site II of the cas locus and LeuO DNA-binding site I of the leuO locus 
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were submitted to MEME Suite (Bailey & Elkan, 1994) (Figure 18A and Figure 13, top panel motif). 
The resulting motif (Figure 13, top panel motif) was used to search the E. coli K12 MG1655 genome 
for putative LeuO DNA-binding sites, using FIMO (Grant et al., 2011). The obtained top scores were 
filtered in respect to their intergenic position as well as their previous identification as presumptive 
LeuO targets in a microarray transcriptome analyses and in a genomic SELEX screening (Stratmann et 
al., 2012, Shimada et al., 2011) (Table 5). Then the sequences of the six top score loci (Figure 18B) 
were used to generate a less stringent motif using MEME Suite (Table 5; Figure 13, bottom panel 
motif). To validate this motif, it was again submitted to FIMO to search the E. coli K12 MG1655 
genome for putative LeuO DNA-binding sites. By this approach we identified 37 sequences with top 
scores, which showed a striking correlation to LeuO targets identified in microarray and the genome 
scale SELEX (Stratmann et al., 2012, Shimada et al., 2011) (see Table 5). The LeuO DNA-binding motif 
(Figure 13, bottom panel motif) presumably represents the DNA-binding site of only one dimeric 
DBD. 
 
Figure 13: LeuO DNA-binding motif.  
Sequences of the palindromic core DNA-binding sites of LeuO site II at cas and of LeuO site I at leuO (shown at 
the top) were used in an iterative approach to determine a DNA-binding consensus sequence. Arrows indicate 
the palindromic sequence. The top sequence logo represents the motif that is based on the LeuO DNA-binding 
sites at cas and leuO and was generated with MEME Suite (Bailey & Elkan, 1994). The bottom motif is based 
on 6 top score hits of the E. coli K12 genome identified by FIMO (see Table 5). The T-11N-A motif typical for 
DNA-binding sites of LysR-type regulators is indicated underneath the logo (Maddocks & Oyston, 2008). 
 
2.8 Regulation of presumptive target loci by LeuO 
LeuO regulates many loci in E. coli and Salmonella (Stratmann et al., 2012, Shimada et al., 2011, 
Dillon et al., 2012). The palindromic DNA binding motif for LeuO shown in Figure 13 was further 
validated with previous data of LeuO DNA-binding and target regulation (Stratmann et al., 2012, 
Shimada et al., 2011) (Figure 13, Table 5). Many putative LeuO targets were identified that harbor a 
presumptive LeuO DNA-binding site and were shown to be LeuO-regulated in the DNA microarray 
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analyses and LeuO bound in genomic SELEX screening (Stratmann et al., 2012, Shimada et al., 2011) 
(Table 5). Nine loci were selected from these putative LeuO targets. These genes harboring a putative 
LeuO DNA-binding site encode proteins of predicted or unknown function. Nine additional loci were 
further selected from the DNA microarray that are regulated between 12-fold to 200-fold when LeuO 
is present and are shown to be LeuO bound targets in the genomic SELEX screening (Stratmann et al., 
2012, Shimada et al., 2011). Some of these putative targets are interesting due to their function in E. 
coli, for others only little is known yet. Many of the putative LeuO regulated targets encode proteins 
for membrane structures, efflux systems or are involved in the bacterial stress response (Dillon et al., 
2012, Shimada et al., 2011). 
To analyze whether transcription of these presumptive targets is indeed regulated by LeuO, I 
constructed lacZ transcriptional fusions of the promoter regions of the putative target loci. The 
cloned fragments include the intergenic region of the target gene loci and the upstream gene, 
including the promoter and putative regulatory binding sites. The promoter lacZ fusions were 
integrated into the genome of a strain lacking LeuO (ΔleuO) and a strain expressing LeuO 
constitutively (leuOc, miniTn10 insertion upstream of leuO). This allowed determining the expression 
levels of the promoter lacZ fusions in absence and presence of LeuO via β-galactosidase assay. In 
addition, the strains carry a deletion of yjjP-yjjQ-bglJ and (ΔPQ-J) to avoid feedback regulation with 
BglJ-RcsB. The results of the expression analysis (leuOc/ΔleuO) are depicted in Table 1 and show no 
activation (<2-fold) of the promoters of gspC, ybeQ, ybeR, yghT, uspG and sdiA. LeuO slightly 
activates the promoters of ompN, chiA, yafT, ybdO, yghS and yjfI with a 2 to 3-fold increase, 
compared to strains deleted for LeuO. The small RNA encoding micC is moderately activated when 
LeuO is constitutively expressed. The divergent genes envR and envC are also moderately regulated 
by LeuO, showing 5-fold and 4-fold activation, respectively. Of all targets tested, downregulation by 
LeuO is shown only for the promoter lacZ fusion of nmpC (5578 units decrease to 1339 units). The 
promoters of cas and yjjQ are highly regulated by LeuO with 44-fold (compare 7 units and 306 units) 
and a 10-fold activation (compare 1.8 and 18 units), respectively (Table 1). 
Taken together, LeuO regulates the cas promoter, and the bacterial defense system might be one of 
the main targets of LeuO. Most loci identified by searching the genome with the LeuO DNA-binding 
motif are directly regulated by LeuO, although the regulation by LeuO is rather weak. The putative 
LeuO targets gspC, ybeQ, ybeR, yghT, uspG and sdiA show no direct regulation by LeuO. 
Nevertheless, the targets might be regulated indirectly by LeuO or the regulation of some of the 
targets might depend on an effector that increases the effect of LeuO. Several target genes, as ompN, 
micC, cas, ybdO and envR are repressed by H-NS and activated by LeuO, supporting LeuO as a specific 
antagonist of H-NS repression. 
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Table 1: Regulation of presumptive targets by LeuO 
P-lacZ ΔleuO leuOc 
fold 
reg. 
micro-
array 
SELEX function
2)
 references 
ompN
1)
 42 82 2.0 73 
41 
outer membrane porin (Fàbrega et al., 2012) 
micC
1)
 310 1695 5.5 199 small regulatory RNA (Chen et al., 2004) 
cas
1)
 7 306 43.7 65 77 bacterial defense system 
(Barrangou et al., 
2007) 
gspC 150 167 1.1 37 70 inner membrane protein 
(Lomize et al., 2017) 
(Francetic et al., 
2000b) 
chiA
1)
 5.1 15.9 3.1 27 25 endochitinase activity 
(Francetic et al., 
2000a) 
yjjQ
1)
 1.8 18 10.0 n.d. 48 transcriptional repressor 
(Stratmann et al., 
2008, Wiebe et al., 
2015) 
yafT 37 85 2.3 8 6 predicted lipoprotein (Juncker et al., 2003) 
ybdO
1)
 141 285 2.0 23 48 putative LysR-type regulator (Higashi et al., 2016) 
ybeQ 16 23 1.4 43 
10 
oxidative stress response (Krisko et al., 2014) 
ybeR 170 286 1.7 20 predicted polypeptide  
yghS 2.1 4.6 2.2 28 
55 
putative protein  
yghT 23 43 1.9 12 putative protein  
envR
1)
 0.1 0.5 5.0 48 
81 
(acrS) transcriptional regulator (Hirakawa et al., 2008) 
envC
1)
 0.3 1.2 4.0  (acrE) lipoprotein, drug efflux pump (Kobayashi et al., 2001) 
yjfI 50 124 2.5 39 54 conserved protein  
nmpC 5578 1339 4.2 -12 8 general bacterial porin (Zhai & Saier, 2002) 
uspG 8.7 5.2 1.7 -52 7 universal stress protein (Kvint et al., 2003) 
sdiA 46 44 1.0 -17 13 transcription factor (cell division) 
(García-Lara et al., 
1996) 
1)
 H-NS-repressed 
2)
 Description of protein functions were taken from the EcoCyc Database (Karp et al., 2014). 
 
2.9 Autoregulation of PleuO by hyperactive LeuO mutants 
Transcription of leuO is repressed by H-NS and StpA under standard laboratory conditions, while the 
transcription regulator BglJ-RcsB activates leuO (Stratmann et al., 2012). LeuO positively and 
negatively autoregulates the leuO expression. In wild-type cells, LeuO acts as a weak positive 
autoregulator, when provided at high levels from a plasmid (Figure 14, compare 3 to 7 units), as 
described (Chen & Wu, 2005). However, LeuO also acts as a negative autoregulator and inhibits the 
activation of leuO by BglJ-RcsB and derepression of leuO in an hns stpA mutant (Figure 14, compare 
308 units to 19 units), as described by (Stratmann et al., 2012). 
To analyze whether the mutations S120D and M244T, which are hyperactive in Pcas activation, also 
affect other loci, their activity in autoregulation was analyzed. The expression of a chromosomal 
PleuO-lacZ reporter was analyzed in three different strain backgrounds (Figure 14A). In addition, 
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autoregulation by the LeuO-DBD was tested. The LeuO mutants were expressed from a plasmid 
under the control of an IPTG inducible tac promoter. The strain backgrounds include (1) a ΔleuO 
ΔbglJ strain to avoid activation of PleuO by BglJ-RcsB. Additionally, negative autoregulation was 
tested in a BglJ-RcsB positive strain (2), in which bglJ is constitutively expressed by allele bglJc and in 
an hns stpA mutant derivative (3). In both of these strain backgrounds PleuO is active (Figure 14B). 
High expression levels of LeuO and its variants (S120D, M244T and DBD) inhibit activation of PleuO by 
BglJ-RcsB and cause repression in the hns stpA background (Figure 14B, bottom panel). Further 
positive autoregulation remained marginal (Figure 14B). However, at basal expression levels LeuO-
S120D acts as a hyperactive autorepressor in the hns stpA mutant, while it seems to enhance 
activation by BglJ-RcsB (Figure 14B, top panel). In addition, positive autoregulation of PleuO by low 
levels of LeuO-S120D is enhanced (18 units compared to 4 units, Figure 14B, top panel). Basal 
expression levels of M244T and of the DBD had similar effects as wild-type LeuO on PleuO-lacZ in all 
three strain backgrounds. Taken together, LeuO-S120D is hyperactive in autoregulation, but not 
LeuO-M244T. Surprisingly, LeuO-DBD is sufficient for autorepression when expressed at high levels. 
The regulation of PleuO-lacZ was also tested for the LeuO mutants that were shown hyperactive at 
Pcas (T127I, S128P, H142R, Q210R, R218C, A237V, H254R; Figure 5). In addition, LeuO mutants 
S120A, M244A and the double mutant S120D/M244T were included and tested as described before 
at high expression levels (plus IPTG). Under non-activating conditions (ΔleuO ΔbglJ) the additional 
LeuO mutants that were shown hyperactive at Pcas show slightly reduced activity compared to wild-
type LeuO, except LeuO-A237V showing similar activation as the wild-type and the LeuO-S120A 
mutant showing a slightly increased activation of PleuO (Figure 14C, top panel). All tested LeuO 
mutants negatively autoregulated PleuO in the presence of BglJ-RcsB (Figure 14C, middle panel). The 
hyperactive LeuO mutants inhibited activation of PleuO by BglJ-RcsB except LeuO mutants S120A, 
T127I, A237V, M244A and H254R. The autorepression by these LeuO mutants is weaker than the 
wild-type LeuO. 
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Figure 14: Autoregulation of leuO by LeuO and LeuO mutants. 
(A) Autoregulation of leuO was analyzed using a chromosomal PleuO-lacZ reporter (Stratmann et al., 2012) 
and LeuO and LeuO mutants were expressed from a plasmid carrying an IPTG inducible tac promoter (Ptac), a 
p15A replication origin and a kanamycin resistance. (B) The chromosomal PleuO-lacZ reporter was integrated 
in strains ΔleuO Δ(yjjP-yjjQ-bglJ) (T308), T862 ΔleuO (bglJC), and T352 ΔleuO Δ(yjjP-yjjQ-bglJ) Δhns stpA 
(Stratmann et al., 2012). Transformants of these strains with the vector control (pKESK22), and plasmids 
providing LeuO (pKETS5), or LeuO mutants S120D (pKESL104), M244T (pKESL73) and LeuO-DBD (pKESMS63), 
were grown in LB medium with kanamycin to an OD600 of 0.5 without induction (top panel) or with induction 
of leuO expression (plus 1 mM IPTG; bottom panel). (C)Analysis of PleuO autoregulation by additional LeuO 
mutants S120A (pKESL108), T127I (pKESL74), S128P (pKESL75), H142R (pKESL76), Q210R (pKESL77), R218C 
(pKESL78), A237V (pKESL80), M244A (pKESMS1), S120D/M244T (pKESL107), H254R (pKESL101) was tested at 
induced LeuO expression levels (plus IPTG). LeuO mutants showing hyperactivity at Pcas are indicated with 
light grey bars. Mean values of at least 3 independent biological replicates are shown as bars, and error bars 
indicate standard deviations. The statistical significance was calculated by Student’s t-test in comparison to 
wild-type LeuO with **p<0.01 and ***p<0.001. 
 
2.10 Is LeuO activity modulated by an effector? 
Many LysR-type regulators require an effector for activating or repressing transcription (Maddocks & 
Oyston, 2008, van Keulen et al., 1998, Picossi et al., 2007). The described effectors so far, are all 
metabolites, ions or modifications of amino acid residues. For example, arginine and lysine are 
effectors of ArgP (Laishram & Gowrishankar, 2007) and Na+ is an effector of NhaR, the activator of a 
sodium antiporter (Dover & Padan, 2001). However, no effector is known for LeuO, although results 
of this work support the hypothesis that LeuO activity might be regulated by an unknown effector. 
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The LeuO protein harbors the typical cleft of the effector-binding domain (Figure 7) and several 
mutations in this cleft rendered the protein inactive (Figure 8B). The hyperactive LeuO mutants that 
were isolated in this work are also located either in the dimer interface of the LeuO effector-binding 
domain (EBD) or at the entrance of the cleft of the EBD, indicating an important role of this cleft. The 
hyperactive LeuO mutant S120D induces a structural change and alters the activity of LeuO. These 
hints support the hypothesis that the LeuO activity may indeed be modulated by an unknown 
effector and that binding of the effector is required for the LeuO function. 
Under amino acid starvation and in stationary growth phase expression of the leuO gene is 
upregulated (Majumder et al., 2001, Fang et al., 2000). A putative effector might be present under 
the very same conditions. For some LysR-type regulators it is known that their location in the 
genome is closely related to their regulated targets, like operons of metabolic pathways that are 
located divergent from their regulators (Maddocks & Oyston, 2008). The product (or an intermediate 
product) of the regulated synthesis pathway can then in turn act as an effector for the LysR-type 
regulator as a feedback mechanism of the transcriptional regulation (Maddocks & Oyston, 2008, 
Picossi et al., 2007). The leuO gene is located between two operons encoding for enzymes of the 
branched-chain amino acid synthesis (leu and ilvIH). This might hint to an intermediate product of 
the branched-chain amino acid synthesis as an effector for LeuO. The scheme of the synthesis 
pathway of the branched-chain amino acids L-valine, L-leucine and L-isoleucine is shown in Figure 15. 
The precursor of L-valine is α-ketoisovalerate, the L-leucine precursor is α-ketoisocaproate and the 
precursor of L-isoleucine is α-keto-β-methylvalerate. The enzyme transaminase B, encoded in ilvE, 
catalyzes the transamination between the α-keto acids of the precursors and the native amino acid 
(Figure 15). The ilvG gene, which carries a frameshift in K12 wild-type strains was restored to ilvG+. 
 
Results 
39 
 
Figure 15: Metabolic pathways for the biosynthesis of the branched-chain amino acids L-isoleucine, L-valine 
and L-leucine. 
The enzymatic reactions are indicated by arrows and the enzymes with their corresponding genes are shown in 
blue. Figure adapted and modified from (Salmon et al., 2006). 
 
The Pcas-lacZ fusion is a very sensitive reporter for monitoring changes of LeuO activity, when 
comparing a ΔleuO strain (T1281) and a strain expressing leuO constitutively (leuOc, T1295). In order 
to address whether the accumulation of precursors of the branched-chain amino acids in the cells 
affects activation of Pcas by LeuO, the ilvE gene was deleted in strains carrying the Pcas reporter and 
a leuO deletion (ΔleuO, T1927) or expressing leuO constitutively (leuOc, T1933; Figure 16). Cultures of 
these ilvE+ and ΔilvE strains were grown in M9 minimal glucose medium, supplemented with no 
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amino acids, or with all three branched-chain amino acids (L-valine, L-leucine and L-isoleucine) or 
with only one of these amino acids. The cultures were grown to OD600 = 0.5 and the β-galactosidase 
activity was measured (Figure 16B). In the ΔleuO strains, Pcas-lacZ directed the expression of 16 units 
β-galactosidase activation without and with amino acids supplemented. Only a slight decrease is 
detectable when the cells were grown in the presence of L-isoleucine (compare 12 units of +ile with 
16 units when no amino acids are supplemented; Figure 16B, left panel). When LeuO is expressed 
constitutively, Pcas directed 121 units in media with no amino acids supplemented. The Pcas activity 
is slightly increased when only L-leucine or all three amino acids are supplemented (compare 198 
units and 174 units; Figure 16B, right panel). When the cells were grown in the presence of 
L-isoleucine, the Pcas activation by LeuO decreases 2-fold from 121 units to 58 units (Figure 16). 
However, the additional deletion of ilvE has no effect on the Pcas activity in the ΔleuO and leuOc 
strain with and without LeuO. 
To evaluate growth defects that are caused by the deletion of ilvE, the strains leuOc (T1295) and ΔilvE 
leuOc (T1933) were grown for 24 h and the OD600 was measured to generate a growth curve (Figure 
16C). The cultures were again grown in M9 minimal glucose medium and either no, only one or all 
three branched-chain amino acids were supplemented. The growth of the cultures did not differ, 
except for the cells grown in the presence of L-isoleucine (+ile depicted in red, Figure 16C). Growth of 
the culture in isoleucine supplemented medium was delayed compared to cells grown in any of the 
other growth conditions (Figure 16C). Therefore, the 2-fold decrease in the activation of Pcas-lacZ 
may be caused by the growth-retardation. The deletion of ilvE causes no altered growth of the 
bacterial cells compared to the leuOc strain, when the branched-chain amino acids were 
supplemented. The ΔilvE strain needs to be supplemented with all three branched-chain amino acids. 
Although several results in this work support the hypothesis that LeuO might be modulated by an 
unknown effector, the precursors of branched-chain amino acids seemed to have no effect. The 
accumulation of precursors of the branched-chain amino acids did not affect the activity of Pcas by 
LeuO, since the decrease of activation in the presence of isoleucine resulted from a growth-
retardation. It is possible that the accumulation of the amino acid precursors is not sufficient to alter 
the activation of Pcas-lacZ or the β-galactosidase assay is not sensitive enough to detect changes in 
activation. 
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Figure 16: Effect of branched-chain amino acids on Pcas activation by LeuO. 
(A) Reporter strains carrying Pcas-lacZ at the attB site include T1281 [ΔleuO Δ(yjjPQ-bglJ) ΔlacZ], T1927 [ΔleuO 
ΔilvE Δ(yjjPQ-bglJ) ΔlacZ], T1295 [leuOc Δ(yjjPQ-bglJ)] andT1933 [leuOc ΔilvE Δ(yjjPQ-bglJ)]. For β-galactosidase 
assays the O/N cultures were grown in M9 minimal medium with 1% glucose, the media was supplemented 
with amino acids L-valine, L-leucine and L-isoleucine (300 µM), where indicated. The exponential cultures 
were inoculated to an OD600=0.05 and grown to an OD600=0.5 in M9 minimal glucose medium, supplemented 
with no amino acids, with all three branched-chain amino acids (300 µM each) or with only one amino acid. 
Mean values of at least 3 independent biological replicates are shown as bars, and error bars indicate standard 
deviations. The statistical significance was calculated by t-test for each culture condition compared to the 
condition without amino acids supplemented with *p < 0.05 and **p < 0.01. (B) Bacterial growth curve of 
strains T1295 (leuOc) and T1933 (leuOc ΔilvE). For measurement of the growth curve an O/N culture was 
grown in M9 minimal glucose medium, supplemented with no amino acid or with all three branched-chain 
amino acids (300 µM each). Exponential cultures were grown in M9 minimal glucose medium, without amino 
acid supplementation (grey rectangles), with the supplementation of all three branched-chain amino acids 
(green triangles for leuOc; blue rectangles for leuOc ΔilvE) or with only one amino acid (red asterisk for L-
isoleucine; grey cross for L-valine and black circles for L-leucine). The cultures were inoculated to OD600=0.03 
and grown for 24 h and OD600 was measured every hour for 11 hours. 
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3 Discussion 
LeuO is a conserved LysR-type transcriptional regulator (LTTR) of pleiotropic function and a co-
regulator of the abundant nucleoid-associated repressor protein H-NS in Escherichia coli (Ueguchi et 
al., 1998, Stoebel et al., 2008, Shimada et al., 2011). The signals and effectors that modulate the 
activity of the LeuO protein are unknown. In this work the control of LeuO activity was addressed. A 
screen for hyperactive LeuO mutants yielded nine single residue exchanges mapping to the 
presumptive cleft of the C-terminal effector-binding domain (EBD) and dimerization interface of the 
EBD. Low levels of these LeuO mutants are sufficient to fully activate the LeuO-controlled cas 
promoter, while high levels of wild-type LeuO are required for Pcas activation. The crystal structures 
of the EBD of one of these hyperactive mutants, LeuO-S120D, and of wild-type LeuO was solved. 
Comparison of the structures suggests that the mutation triggers an allosteric structural of the EBD, 
which is related to effector-induced structural changes of other LTTRs. This structural change 
transmits to the arrangement of the DNA-binding domains and is reflected in an enhanced DNA-
binding specificity of the LeuO-S120D as shown by DNase I footprinting (Figure 17). A detailed 
analysis of the DNA-binding sites unraveled a palindromic sequence, which allowed defining a DNA-
binding motif for LeuO. LeuO-S120D might mimic an effector-bound state, which regulates a putative 
different set of target loci than the wild-type LeuO. The LeuO mutants can be used as a tool to study 
the mechanism of transcriptional regulation and the H-NS co-regulation. 
 
3.1 DNA-binding of LeuO and LeuO-S120D 
DNase I footprinting of LeuO DNA-binding sites at the cas locus (Westra et al., 2010) with a broad 
concentration range of wild-type and LeuO-S120D demonstrated that DNA-binding by LeuO-S120D is 
more specific and distinct than by wild-type LeuO. Intriguingly, DNase I footprinting with just the 
dimeric DNA-binding domain (DBD) of LeuO yielded a similarly distinct and specific pattern as LeuO-
S120D. The distinct DNase I footprint pattern is in agreement with binding of a presumptive LeuO-
S120D tetramer (carrying two dimeric DBDs) to a high-affinity palindromic DNA-binding-site (“core-
site”) and secondary DNA-binding site (Figure 17). For this high-affinity core DNA-binding site a 
specific consensus sequence motif was defined. The crystal structures of the EBDs of LeuO and LeuO-
S120D were solved in this work. The structural change observed for the LeuO-S120D mutant 
correlates with an enhanced DNA-binding specificity and distinct DNA-binding pattern at the cas 
LeuO-binding sites. It seems possible that wild-type LeuO adopts a conformation that is poorly 
competent in DNA-binding, while the S120D mutant is fully active. Similarly, apo-AphB may not bind 
DNA, while the structure of the AphB-N100E mutant suggests that this effector-independent mutant 
binds DNA and presumably mimics a ligand-bound AphB (Taylor et al., 2012). The model that the 
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LeuO-S120D mutation likewise allows (or enhances) DNA-binding is supported by the fact that a low 
LeuO-S120D concentration is sufficient to footprint the cas LeuO binding-site II (Figure 11A). S120D 
shows additional protection from DNase I digestion between the two LeuO DNA-binding sites I and II, 
indicated by an additional hypersensitive site (open arrowhead, Figure 11A). These additional DNA-
binding sites suggest that a higher order complex of two or more tetramers might be formed for the 
hyperactive LeuO-S120D. Further, the DNase I footprint pattern of LeuO-S120D is very similar to that 
of the isolated dimeric LeuO-DBD which binds DNA without steric hindrance (Figure 11). Taken 
together, the data indicate that the hyperactive mutants of LeuO, in particular S120D, may mimic an 
effector-induced form of LeuO with enhanced DNA-binding specificity. 
However, the crystallization of the full-length proteins failed so far. The structure of full-length LeuO 
and hyperactive LeuO-S120D or their oligomeric state might be too flexible for crystallization. 
Possibly, a co-crystallization approach of LeuO-S120D with a short DNA-fragment that comprises the 
specific consensus sequence motif for LeuO might be successful. A complex of the purified protein 
with short DNA fragments representing the high-affinity core DNA-binding site might lead to a 
stabilized complex that can further be used for crystallization. 
 
Figure 17: A schematic model for DNA-binding of a LeuO tetramer.  
LeuO monomers are depicted with a spheric DNA-binding domain (DBD) and a rectangular effector-binding 
domain (EBD), connected by a linker. In the tetrameric structure, two EBDs dimerize in a head-to-tail 
orientation through a conserved dimerization interface (here: blue with light blue and grey with light grey). The 
DBDs dimerize via the α-helical linker (here: blue with light grey and grey with light blue). Binding of the LeuO 
tetramer to the DNA might be dependent on a specific angle and distance of the DBDs, which are altered by 
structural changes of the EBDs, either upon effector-binding or mutation of an amino acid. One DBD dimer 
binds to the high affinity DNA-binding site (core-site shown in green), while the other DBD dimer binds to an 
adjacent DNA-binding site. 
 
3.2 Is LeuO activity regulated by an effector? 
The LeuO-S120D mutant showed an enhanced DNA-binding specificity and distinct DNA-binding 
pattern and may mimic an effector-induced state of LeuO. Comparing the crystal structures of the 
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EBDs of wild-type LeuO and the S120D mutant suggest that the mutation (S120D) induces a 
structural change of the two EBD subdomains RD-1 and RD-2. Further, the side-chain of Arg218 is re-
oriented, which resides at the presumptive cleft of the effector-binding domain. The mutation of 
Arg218 to Glu, Ala, and Cys also causes hyperactivity, indicating that the positively charged 
guanidinium group of Arginine may be crucial for an inactive LeuO conformation. These structural 
changes might also be triggered by binding of an effector regulating the activity of LeuO in response 
to a signal. 
A putative effector regulating LeuO activity is also supported by the putative chloride ion binding 
next to the rather hydrophobic cleft of the LeuO-EBD. The putative chloride ion locates in the cleft of 
the EBD and is coordinated mainly by the backbone amide of Met243 and the l side-chain hydroxyl 
group of Ser120. This putative chloride ion is only found in the wild-type protein and not in the 
hyperactive mutant where this “space” is occupied by the re-oriented Arg218 (Figure 7). It might be 
possible that the chloride ion stabilizes the wild-type protein. To date, no effector of LeuO is known. 
However, a metabolite with a negative charge and a hydrophobic moiety might bind in the cleft of 
the EBD and therefore induce structural changes that alter the DNA-binding of LeuO. Similar effector-
induced or mutation-based rearrangements have been described for other structures of LTTRs 
including DntR, AphB, BenM, and OxyR (Lerche et al., 2016, Devesse et al., 2011, Taylor et al., 2012, 
Ruangprasert et al., 2010, Ezezika et al., 2007, Jo et al., 2015, Kullik et al., 1995).  
However, some LTTRs are bound by several effectors and for some several effector-binding sites 
have been identified. For example, in NdhR a second effector-binding site in the dimeric interface 
between two EBDs is formed (Jiang et al., 2018). Several hyperactive LeuO mutants as H142R, A237V, 
H254R and Q210R locate rather distant from the cleft of the EBD, but still in the interface between 
two dimerizing EBDs. These mutants may cause hyperactivity by stabilizing the dimer or by affecting 
a secondary effector-binding site in LeuO. 
Several described LTTRs map next to the genes they regulate, for example BenM and IlvY (Maddocks 
& Oyston, 2008, Bundy et al., 2002, Wek & Hatfield, 1988). The leuO gene is located between two 
operons related to branched-chain amino acid synthesis. The leu operon encodes for leucine 
synthesis and the ilvIH operon encodes for enzymes involved in the synthesis of valine and 
isoleucine. In addition, leuO is upregulated in stationary growth phase and by amino acid starvation 
(Fang et al., 2000, Majumder et al., 2001). A putative effector regulating LeuO might be present in 
the same conditions when LeuO is upregulated or when an intermediate product of the amino acid 
synthesis is present. Nonetheless, the accumulation of precursors of branched-chain amino acids had 
no striking effect on the LeuO activity (Figure 16). Possible reasons might be insufficient levels of the 
precursors or that an earlier starvation signal leads to the activation of LeuO. However, the Pcas-lacZ 
Discussion 
45 
reporter can be a valuable tool for searching an effector. Another approach to identify putative 
effectors regulating the LeuO activity, a fluorescence-based thermal stability assay (Thermoflour 
screen) can screen for possible metabolites (in solution conditions) that, when bound to the protein 
induces structural changes and enhance the protein stability (Boivin et al., 2013). To identify an 
effector for LeuO, another possible approach might be a metabolite library screen using the Pcas 
reporter or another LeuO target gene reporter. LeuO strongly activates Pcas, associated with the 
bacterial defense system in E. coli against foreign DNA and phage invasion (Barrangou et al., 2007). It 
is also possible that a putative effector of LeuO is present (and induces the structural changes leading 
to increased binding specificity like S120D) when cas is activated by LeuO. Components of foreign 
DNA or elements of invading phages might be metabolites that bind to LeuO and alter its activity as 
an effector. 
 
3.3 The spectrum of LeuO target loci 
Up to date, LeuO target genes and their regulation by LeuO have been identified and studied with 
wild-type LeuO only. These studies led to the identification of a broad spectrum of target genes and a 
rather weak consensus sequence for the LeuO DNA-binding site (Dillon et al., 2012, Ishihama et al., 
2016, Shimada et al., 2011). The palindromic consensus sequence defined here on the basis of the 
core-DNA-binding site detected by DNase I footprinting is very specific, but it is also in agreement 
with the consensus motif characterized before (Dillon et al., 2012). The bioinformatic analysis using 
MEME Suite and FIMO in an iterative approach yielded a good correlation of the top LeuO target 
genes. However, not all LeuO targets could be identified in this approach. Assuming that LeuO 
activity is indeed effector-controlled the spectrum of LeuO target genes might change upon effector-
binding, with some targets being up-regulated, others down-regulated or not affected at all. Such a 
scenario has been characterized for example for the control of E. coli ArgP activity by the effectors 
lysine (acting inhibitory) and arginine (acting positively) (Nguyen Le Minh et al., 2018, Laishram & 
Gowrishankar, 2007). In this study, the effect of the LeuO mutants that are hyperactive in regulation 
of the cas promoter, were compared to a second LeuO target, the autoregulated leuO promoter. 
Interestingly, S120D as well as S128P, H142R, Q210R, R218C, appear hyperactive in positive and in 
negative leuO autoregulation. The other hyperactive LeuO mutants T127I, A237V, and H254R 
regulate the leuO promoter similar to wild-type LeuO. This indicates that indeed target-gene specific 
differences may exist. Depending on the arrangement of the core and auxiliary LeuO DNA-binding 
sites in a LeuO-regulated promoter, effector-binding or a mutations-causing hyperactivity in cas 
regulation may have no effect, enhance competition or co-regulation with H-NS, and allow or 
prevent interaction with RNA-polymerase. Thus the spectrum of LeuO target genes may vary in 
dependence of an effector, which could be addressed in the future for example by analyzing other 
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hyperactive LeuO mutants that may vary from LeuO-S120D. LeuO regulated targets analyzed here 
were mainly weakly regulated by wild-type LeuO (Table 5). The target loci were identified using high 
levels of wild-type LeuO. The LeuO-S120D mutant might mimic an effector-induced state and as a 
next step, analyzing the transcriptome by differential RNA seq, of cells expressing genomic LeuO-
S120D instead of the endogenous LeuO, is a promising approach to identify effector-dependent 
targets of LeuO. 
 
3.4 How does LeuO regulate transcription? 
The relationship between the LysR-type regulator LeuO and the global silencer H-NS is quite versatile 
and different aspects have been analyzed in the past. Many LeuO-activated target loci are repressed 
by H-NS and LeuO is therefore considered an H-NS antagonist (Stoebel et al., 2008, Hernández-Lucas 
& Calva, 2012). LeuO can also function as a “back-up” of H-NS and repress target loci when H-NS is 
not present (Espinosa & Casadesús, 2014). In addition, genomic SELEX data shows a significant 
overlap of co-regulation of LeuO target loci by H-NS (Stratmann et al., 2012, Dillon et al., 2012, 
Shimada et al., 2011). However, the exact mechanisms behind the binding of both regulators to the 
target DNA and the resulting regulation remain elusive. The binding sites for LeuO and H-NS may 
determine whether LeuO acts as an activator or repressor. For the cas promoter it was proposed that 
LeuO does not compete for binding with LeuO and that LeuO might limit the spreading of H-NS into 
the promoter region (Westra et al., 2010). The gene ompS1 is co-regulated by LeuO and H-NS and it 
was suggested that activation by LeuO is presumably achieved when H-NS and LeuO compete for 
binding to the DNA (De la Cruz et al., 2007). The spreading of the H-NS nucleocomplex can also be 
delimited by LeuO by transcription induced changes in DNA supercoiling (Chen & Wu, 2005). An in 
vitro transcription assay might shed light on the mechanism of the co-regulation with H-NS when the 
LeuO-S120D mutant alters the complex formation on the DNA or the removal of H-NS from the DNA. 
The nine hyperactive LeuO mutants showed differences in the regulation of cas and leuO, which 
might be caused by a different DNA-binding specificity, altered stabilization of the protein dimer or 
tetramer, or an altered interaction with H-NS. A more detailed analysis of the mutants may give new 
insights in the function of LeuO and its co-regulation with H-NS. Differences in the DNA-binding by 
the hyperactive LeuO mutants will be analyzed using surface plasmon resonance (SPR) spectroscopy 
to determine the binding affinity. 
Another approach of characterization the interaction between H-NS and LeuO is the introduction of a 
non-canonical and UV-crosslinkable amino acid. The interactions with other transcription factors, 
with H-NS and the RNA polymerase can be analyzed, as well as the presumed dimerization and 
tetramer formation of LeuO. 
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3.5 Approaches for analyzing LysR-type transcriptional regulators 
In E. coli 46 LysR-type transcriptional regulators (LTTRs) are described: for 17 LTTRs target genes and 
signals that modulate their activity are described, for 10 LTTRs some aspects of their function are 
known but their regulation and possible effectors are unidentified and 19 LTTRs are of unknown 
function. Characterizing LTTRs remains experimentally challenging due to their intrinsic structural 
properties and variable DNA-binding mode, but also the identification of effectors is a difficult task.  
Target loci of LTTRs that were identified in the past used rather high and artificial concentrations of 
the wild-type protein, for example in microarray transcriptome analyses or genome scale SELEX 
screenings. These high protein concentrations lead to unspecific DNA-binding and target loci 
identification that might not be regulated in native cell conditions. To circumvent the problem of 
unspecific DNA-binding, the DNA-binding domain (DBD) might be a promising approach for RNA seq, 
due to specific DNA-binding and the possible lower protein concentrations that were needed. An 
already described target locus might be of good use as a reporter. Using for example a reporter lacZ 
fusion, hyperactive mutants can be screened, as described here for LeuO (see chapter 2.1). Mutants 
of the LTTR can shed light to a different set of target loci, to structural characteristics and even 
indicate a metabolite that alters the activity as an effector. To further analyze the function and the 
oligomeric state of an LTTR the protein can be crystallized to solve the structure. It is possible that 
putative metabolites that alter the activity of the LTTR co-crystallize. Another approach to identify 
effectors of LTTRs might be a metabolic library screen. 
 
Materials and Methods 
48 
4 Materials and Methods 
4.1 Media, antibiotics and bacterial cultivation 
Bacterial cultures of Escherichia coli K12 were grown in LB medium (5 g/l Bacto Yeast extract, 10 g/l 
Bacto Tryptone, 5 g/l NaCl), for plates 15 g/l Bacto Agar was added. Antibiotics were added as 
indicated in final concentrations of 50 µg/ml ampicillin, 15 µg/ml chloramphenicol, 50 μg/ml 
spectinomycin, 12 μg/ml tetracyclin and 25 µg/ml kanamycin. IPTG (isopropyl-β,D-
thiogalactopyranoside) was added to liquid cultures at a concentration of 1 mM and to plates at a 
concentration of 200 µM. X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) was added to a 
final concentration of 40 µg/ml to tryptone plates, where indicated. 
4.2 Standard molecular techniques 
Standard molecular techniques like agarose gel electrophoresis, molecular cloning and PCR were 
carried out according to published protocols (Ausubel, 2005). Sequencing was performed by GATC 
Biotech AG, Konstanz, Germany. 
4.3 Bacterial strains, plasmids and oligonucleotides 
Escherichia coli K12 strains used and constructed in this study are listed in Table 2, plasmids are given 
in Table 3 and sequences of oligonucleotides are summarized in Table 4. 
Table 2: Escherichia coli K12 strains 
strain genotype
a)
 reference/ construction 
BW30270 MG1655 rph
+
 (laboratory collection S3839) CGSC#7925 
C41(DE3) BL21(DE3) derivate selected for expression of toxic proteins (Miroux & Walker, 1996) 
T1241 BW30270 ilvG
+
 (motile) (Pannen et al., 2016) 
S1729 leuOc (leuO-Y1::miniTn10-cmR; constitutive expression of leuO) (Madhusudan et al., 2005) 
S4197 BW30270 ilvG
+
 ΔlacZ (non-motile) (Venkatesh et al., 2010) 
T23 S4197 Δ(yjjP-yjjQ-bglJ)FRT (Stratmann et al., 2012) 
T61 S4197 ΔleuO::KD4-kanR lab collection  
(T. Stratmann) 
T70 S4197 Δ(yjjP-yjjQ-bglJ)::KD3-cmR  (Venkatesh et al., 2010) 
T314 S4197 ΔleuOFRT Δ(yjjP-yjjQ-bglJ)FRT (Venkatesh et al., 2010) 
T1146 S4197 leuOC (=leuO-Y1::mTn10-cmR) S4197 x T4GT7(S1729), lab 
collection (T. Stratmann) 
T1148 S4197 ΔyjjP-yjjQ-bglJ::FRT leuOC T23 x T4GT7(S1729), lab 
collection (T. Stratmann) 
T1610 T314 attB::(Pcas lacZ aadA) / F’ Tn10 (TetR) proA
+
B
+
 lacI
q
 Δ(lacZ)M15 T1281 x F’ (XL1-Blue) 
conjugation 
E. coli K12 strains with gene deletions constructed as described (Datsenko & Wanner, 2000, Kolmsee & 
Hengge, 2011) 
T1922 T23 ΔilvE::KD4-kanR T23/pKD46 x T967/T968 of 
pKD4 
T1923 T1148 ΔilvE::KD4-kanR T1148/pKD46 x T967/T968 
of pKD4 
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Table 2: Escherichia coli K12 strains 
strain genotype
a)
 reference/ construction 
T1924 T1281 ΔilvE::KD4-kanR T1281/pKD46 x T967/T968 
of pKD4 
T1925 T23 ΔilvE::FRT T1922 x pCP20 
T1926 T1148 ΔilvE::FRT T1923 x pCP20 
T1927 T1281 ΔilvE::FRT T1924 x pCP20 
T1928 T1295 ΔilvE::KD4-kanR T1295/pKD46 x T967/T968 
of pKD4 
T1929 T314 ΔilvE::KD3-cmR T314/pKD46 x T967/T968 
of pKD3 
T1933 T1295 ΔilvE::FRT T1928 x pCP20 
T1934 T314 ΔilvE::FRT T1929 x pCP20 
T1876 T1241 ΔleuO::ccdB neo T1241/pKD46 x T994/T995 
of pKILL45 
T1877 S3839 ΔleuO::ccdB neo S3839/pKD46 x T994/T995 
of pKILL45 
T1921 T1146 PleuOc ΔleuO::ccdB neo T1146/pKD46 x T994/T995 
of pKILL45 
T1930 S3839 leuO-S120D/M244T T1877/pKD46 x T996/T997 
of pKESL107 
T1931 S3839 leuO-M244T T1877/pKD46 x T996/T997 
of pKESL73 
T1932 S3839 leuO-S120D T1877/pKD46 T996/T997 
of pKESL104 
T1938 S4197 PleuOc leuO-M244T T1921/pKD46 x T996/T997 
of pKESL73 
E. coli K12 strains constructed by phage transduction 
T1988 BW30270 ΔleuO::KD4-kanR BW30270 x T4GT7 (T61) 
T1989 BW30270 ΔyjjP-yjjQ-bglJ::KD3-cmR BW30270 x T4GT7 (T70) 
T1990 BW30270 Δ(yjjP-yjjQ-bglJ)::KD3-cmR, leuO-S120D T1932 x T4GT7 (T70) 
T1991 BW30270 Δ(yjjP-yjjQ-bglJ)::KD3-cmR, leuO-M244T T1931 x T4GT7 (T70) 
T2009 BW30270 ΔleuO::FRT T1988 x pCP20 
T2010 BW30270 ΔyjjP-yjjQ-bglJ::FRT T1989 x pCP20 
T2011 BW30270 ΔyjjP-yjjQ-bglJ::FRT leuO-S120D T1990 x pCP20 
T2012 BW30270 ΔyjjP-yjjQ-bglJ::FRT leuO-M244T T1991 x pCP20 
E. coli K12 strains with promoter lacZ fusion at attB integration site
 b)
 
T308 S4197 attB::(PleuO lacZ aadA) ΔleuOFRT Δ(yjjP-yjjQ-bglJ)FRT (Stratmann et al., 2012) 
T352 S4197 attB::(PleuO lacZ aadA) ΔleuOFRT Δ(yjjP-yjjQ-bglJ)FRT ΔhnsFRT 
stpA::tet 
(Stratmann et al., 2012) 
T568 T314 attB::(Pbgl t1RAT bglG lacZ aadA) (Venkatesh et al., 2010) 
T862 S4197 attB::(PleuO lacZ aadA) ΔleuOFRT (bglJC) (Stratmann et al., 2012) 
T1188 T314 attB::(PchiA lacZ aadA) (Salscheider et al., 2014) 
T1275 T314 attB::(PuspG lacZ aadA) T314/pLDR8 x pKESL31 
T1277 T314 attB::(PompN lacZ aadA) T314/pLDR8 x pKESL32 
T1279 T314 attB::(PmicC lacZ aadA) T314/pLDR8 x pKESL33 
T1281 T314 attB::(Pcas lacZ aadA) T314/pLDR8 x pKESL34 
T1291 T1148 attB::(PuspG lacZ aadA) T1148/pLDR8 x pKESL31 
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Table 2: Escherichia coli K12 strains 
strain genotype
a)
 reference/ construction 
T1293 T1148 attB::(PompN lacZ aadA) T1148/pLDR8 x pKESL32 
T1295 T1148 attB::(Pcas lacZ aadA) T1148/pLDR8 x pKESL34 
T1313 T1148 attB::(PchiA lacZ aadA) T1148/pLDR8 x pKESL9 
T1317 T1148 attB::(PmicC lacZ aadA) T1148/pLDR8 x pKESL33 
T1319 T314 attB::(PyjjQ lacZ aadA) T314/pLDR8 x pKES111 
T1323 T1148 attB::(PyjjQ lacZ aadA) T1148/pLDR8 x pKES111 
T1494 T314 attB::(PsdiA lacZ aadA) T314/pLDR8 x pKESL36 
T1509 T314 attB::(PnmpC lacZ aadA) T314/pLDR8 x pKESL35 
T1511 T1148 attB::(PnmpC lacZ aadA) T1148/pLDR8 x pKESL35 
T1515 T314 attB::(PgspC lacZ aadA) T314/pLDR8 x pKESL38 
T1517 T1148 attB:: (PgspC lacZ aadA) T1148/pLDR8 x pKESL38 
T1527 T1148 attB::(PsdiA lacZ aadA) T1148/pLDR8 x pKESL36 
T2396 T314 attB::(PyafT lacZ aadA) T314/pLDR8 x pKESMS70 
T2397 T1148 attB::(PyafT lacZ aadA) T1148/pLDR8 x pKESMS70 
T2398 T314 attB::(PybdO lacZ aadA) T314/pLDR8 x pKESMS71 
T2399 T1148 attB::(PybdO lacZ aadA) T1148/pLDR8 x pKESMS71 
T2400 T314 attB::(PybeQ lacZ aadA) T314/pLDR8 x pKESMS77 
T2401 T1148 attB::(PybeQ lacZ aadA) T1148/pLDR8 x pKESMS77 
T2402 T314 attB::(PybeR lacZ aadA) T314/pLDR8 x pKESMS72 
T2403 T1148 attB::(PybeR lacZ aadA) T1148/pLDR8 x pKESMS72 
T2404 T314 attB::(PyghS lacZ aadA) T314/pLDR8 x pKESMS73 
T2405 T1148 attB::(PyghS lacZ aadA) T1148/pLDR8 x pKESMS73 
T2406 T314 attB::(PyghT lacZ aadA) T314/pLDR8 x pKESMS74 
T2407 T1148 attB::(PyghT lacZ aadA) T1148/pLDR8 x pKESMS74 
T2408 T314 attB::(PenvR lacZ aadA) T314/pLDR8 x pKESMS78 
T2409 T1148 attB::(PenvR lacZ aadA) T1148/pLDR8 x pKESMS78 
T2410 T314 attB::(PenvC lacZ aadA) T314/pLDR8 x pKESMS75 
T2411 T1148 attB::(PenvC lacZ aadA) T1148/pLDR8 x pKESMS75 
T2412 T314 attB::(PyjfI lacZ aadA) T314/pLDR8 x pKESMS76 
T2413 T1148 attB::(PyjfI lacZ aadA) T1148/pLDR8 x pKESMS76 
a)
 The following abbreviations and genetic designations are used: FRT for Flp recombinase target site, aadA for 
spectinomycin resistance, tet for tetracycline resistance, neo for kanamycin resistance. Allele bglJC refers to 
allele yjjQ/bglJ-Y6::mTn10-cmR, directing constitutive expression of bglJ (Madhusudan et al., 2005). Allele 
leuOc refers to leuO-Y1::mTn10-cmR, directing constitutive leuO expression. Chromosomal deletions and 
insertion of mutations were constructed by λ-Red mediated recombination (Datsenko & Wanner, 2000) or 
(Kolmsee & Hengge, 2011) described in chapter 4.9 and 4.10. Flipping of the FRT (Flp recombinant target site) 
flanked resistance cassette by Flp recombinase was performed using plasmid pCP20 (x pCP20). T4 phage 
transduction was performed as described (Wilson et al., 1979) and is represented as “recipient strain x phage 
T4GT7 (donor strain)”, described in chapter 4.11. 
b)
 Construction of strains was performed by integration promoter lacZ reporter fusions into the chromosomal 
attB site (indicated as strain/pLDR8 x plasmid designation) as described (Diederich et al., 1992). In brief, 
integration of reporter lacZ constructs into the phage λ attB site was performed using replication origin-less re-
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ligated BamHI fragments of the indicated plasmids carrying a promoter lacZ fusion, the attP-site and the aadA 
gene for selection by spectinomycin. All alleles were confirmed by PCR. 
 
Table 3: Plasmids  
plasmid features
a
 reference/ construction
b
 
pCP20 cI857 λ-PR flp in pSC101 rep
ts
 ampR (Cherepanov & Wackernagel, 
1995) 
pET-22b(+) T7 promoter, His6 expression vector ampR Novagen® 
pFDY157 lacI
q
 Ptac lacZ rrnB-T1,T2 pBR-ori ampR lab collection 
pKD3 FRT-cmR-FRT oriRγ ampR (Datsenko & Wanner, 2000) 
pKD4 FRT-kanR-FRT oriRγ ampR (Datsenko & Wanner, 2000) 
pKD45 rhaP 3 ccdB (L50F) neo cassette inR6Kgamma (Kolmsee & Hengge, 2011) 
pKD46 araC PBAD γ-β-exo in pSC101 rep
ts
 ampR (Datsenko & Wanner, 2000) 
pKILL45 rhaP 3 ccdB(wt) neo cassette inR6Kgamma in pKD45 cloned with (OA001/OA002) 
pLDR8 cI857 PR λ-int in pSC101 rep
ts
 kanR (Diederich et al., 1992) 
pKES268 PlacUV5 MCS lacZ ori-p15A kanR attP aadA (Salscheider et al., 2014) 
pKES334 lacI
q
 Ptac MCS rrnB-T1,T2 pBR-ori ampR pFDY157 x adaptor 
(OA576/OA577) 
pKESK22 lacI
q
 Ptac MCS in ori-p15A kanR (Stratmann et al., 2008) 
pKETS2 PleuO(-846 to +45)-XbaI-TAA lacZ in p15A kanR attP aadA lab collection, (T. Stratmann) 
pKETS5 leuO in pKESK22 (Stratmann et al., 2012) 
pKESK10 PlacUV5 bglG ori-pSC cmR (Dole et al., 2002) 
pKETS24 PlacUV5 MCS ori-pSC cmR MCS in pKESK10 
pKETS25 PlacUV5 leuO ori-pSC cmR (Breddermann & Schnetz, 2016) 
pKES111 PyjjQ lacZ in pACYC (Stratmann et al., 2008) 
pKESL9 PchiA lacZ in pKES268 (Salscheider et al., 2014) 
pKESL31 PuspG lacZ in pKES268 cloned with T734/T735 
pKESL32 PompN lacZ in pKES268 cloned with T740/T741 
pKESL33 PmicC lacZ in pKES268 cloned withT738/T739 
pKESL34 Pcas lacZ in pKES268 cloned with T736/T737 
pKESL35 PnmpC lacZ in pKES268 cloned with T806/T807 
pKESL36 PsdiA lacZ in pKES268 cloned with TT808/T809 
pKESL38 PgspC lacZ in pKES268 cloned with T810/T811 
pKESL39 leuO in pKETS24 directed leuO mutagenesis 
pKESL40 leuO-S120D(AGC>GAT)+ E111D(GAA>GAC) in pKETS24 directed leuO mutagenesis 
pKESL61 leuO-M243E(ATG>GAA) in pKETS24 directed leuO mutagenesis 
pKESL62 leuO-L263E(CTG>GAA) in pKETS24 directed leuO mutagenesis 
pKESL64 leuO-I125E(ATT>GAA) in pKETS24 directed leuO mutagenesis 
pKESL65 leuO-I125E(ATT>GAA)+ V118I(GTT>ATT) in pKETS24 directed leuO mutagenesis 
pKESL67 leuO-F219E(TTC>GAA) in pKETS24 directed leuO mutagenesis 
pKESL68 leuO-L122E(TTA>GGA)+ H115Y(CAT>TAT) in pKETS24 directed leuO mutagenesis 
pKESL69 leuO-P121D(CCG>GAT) in pKETS24 directed leuO mutagenesis 
pKESL70 leuO-Y168E(TAT>GAA) in pKETS24 directed leuO mutagenesis 
pKESL71 leuO-S120D(AGC>GAT)+ E111D(GAA>GAC) in pKESK22  directed leuO mutagenesis 
pKESL72 leuO-S120D(AGC>GAT)+ E111D(GAA>GAC) 
+D205N(GAT>AAT) in pKESK22 
screen (T568) 
pKESL73 leuO-M244T(ATG>ACG) in pKESK22 screen (T1281, *) 
pKESL74 leuO-T127I(ACC>ATC) in pKESK22 screen (T1610) 
pKESL75 leuO-S128P(TCG>CCG) in pKESK22 screen (T1610, 3x) 
pKESL76 leuO-H142R(CAT>CGT) in pKESK22 screen (T1610, 2x) 
pKESL77 leuO-Q210R(CAA>CGA) in pKESK22 screen (T1610, 2x) 
pKESL78 leuO-R218C(CGT>TGT) in pKESK22 screen (T1610) 
pKESL79 leuO-V230I(GTA>ATA)+ M244T(ATG>ACG) in pKESK22 screen (T1610, *) 
pKESL80 leuO-A237V(GCG>GTG) in pKESK22 screen (T1610, 2x) 
pKESL101 leuO-H254R(CAT>CGT)+ R74R(CGT>CGC) in pKESK22 screen (T1610, 2x) 
pKESL102 leuO-S120D(AGC>GAT) in pKETS24 directed leuO mutagenesis 
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Table 3: Plasmids  
plasmid features
a
 reference/ construction
b
 
pKESL103 leuO-L122E(TTA>GGA) in pKETS24 directed leuO mutagenesis 
pKESL104 leuO-S120D(AGC>GAT) in pKESK22 directed leuO mutagenesis 
pKESL105 leuO-S120D(AGC>GAT)+ C119S(TGC>AGC) in pKESK22 directed leuO mutagenesis 
pKESL106 leuO-L122E(TTA>GGA) in pKESK22 directed leuO mutagenesis 
pKESL107 leuO-S120D(AGC>GAT)+ M244T(ATG>ACG) in pKESK22 directed leuO mutagenesis 
pKESL108 leuO-S120A(AGC>GCG) in pKESK22 directed leuO mutagenesis 
pKESL109 leuO-M244A(ATG>GCG)+ G240V(GGC>GTC) in pKESK22 directed leuO mutagenesis 
pKESL110 leuO-M244A(ATG>GCG)+ M34V(ATG>GTG) in pKESK22 directed leuO mutagenesis 
pKESL221 leuO-N150A(AAT>GCT) in pKESK22 directed leuO mutagenesis 
pKESL222 leuO-N152A(AAC>GCC) in pKESK22 directed leuO mutagenesis 
pKESL223 leuO-H155A(CAT>GCT) in pKESK22 directed leuO mutagenesis 
pKESL224 leuO-Q156A(CAG>GCG) in pKESK22 directed leuO mutagenesis 
pKESL225 leuO-H172A(CAT>GCT) in pKESK22 directed leuO mutagenesis 
pKESL226 leuO-R173A(CGT>GCT) in pKESK22 directed leuO mutagenesis 
pKESL227 leuO-K232A(AAG>GCG) in pKESK22 directed leuO mutagenesis 
pKESL228 leuO-R158A(CGT>GCT)+ E175E(GAA>GAG)in pKESK22 directed leuO mutagenesis 
pKESL229 leuO-Q151A(CAG>GCG) in pKESK22 directed leuO mutagenesis 
pKESL230 leuO-H204A(CAT>GCT) in pKESK22 directed leuO mutagenesis 
pKESL231 leuO-N150E(AAT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL232 leuO-Q151E(CAG>GAG) in pKESK22 directed leuO mutagenesis 
pKESL233 leuO-N152E(AAC>GAG) in pKESK22 directed leuO mutagenesis 
pKESL234 leuO-H155E(CAT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL235 leuO-R158E(CGT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL236 leuO-H172E(CAT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL237 leuO-H204E(CAT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL238 leuO-R218A(CGT>GCT) in pKESK22 directed leuO mutagenesis 
pKESL239 leuO-W226A(TGG>GCG) in pKESK22 directed leuO mutagenesis 
pKESL240 leuO-W226E(TGG>GAG) in pKESK22 directed leuO mutagenesis 
pKESL241 leuO-Q156E(CAG>GAG) in pKESK22 directed leuO mutagenesis 
pKESL242 leuO-R173E(CGT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL243 leuO-R218E(CGT>GAG) in pKESK22 directed leuO mutagenesis 
pKESL244 leuO-K232E(AAG>GAG) in pKESK22 directed leuO mutagenesis 
pKESMS1 leuO-M244A(ATG>GCG) in pKESK22 directed leuO mutagenesis 
pKESMS3 leuO-S120D-EBD-His6 in pET-22b(+) protein purification 
pKESMS16 leuO-His6 in pET-22b(+) protein purification 
pKESMS17 leuO-S120D-His6 in pET-22b(+) protein purification 
pKESMS21 leuO-EBD-His6 in pET-22b(+) protein purification 
pKESMS38 leuO-His6 in pFDY157 cloned with S326/S400 
pKESMS63 leuO-DBD in pKESK22 cloned with S326/OA440 
pKESMS64 leuO-C117S(TGT>AGC)+ L263L(CTG>CTA) in pKESK22 directed leuO mutagenesis 
pKESMS65 leuO-C119S(TGC>AGC) in pKESK22 directed leuO mutagenesis 
pKESMS66 leuO-C119D(TGC>GAT) in pKESK22 directed leuO mutagenesis 
pKESMS67 leuO-C117D(TGT>GAT) in pKESK22 directed leuO mutagenesis 
pKESMS68 leuO-DBD-His6 in pET-22b(+) protein purification 
pKESMS70 PyafT lacZ in pKES268 cloned with OA514/OA515 
pKESMS71 PybdO lacZ in pKES268 cloned with OA516/OA517 
pKESMS72 PybeR lacZ in pKES268 cloned with OA520/OA521 
pKESMS73 PyghS lacZ in pKES268 cloned with OA522/OA523 
pKESMS74 PyghT lacZ in pKES268 cloned with OA524/OA525 
pKESMS75 PenvC lacZ in pKES268 cloned with OA528/OA529 
pKESMS76 PyjfI lacZ in pKES268 cloned with OA530/OA531 
pKESMS77 PybeQ lacZ in pKES268 cloned with OA518/OA519 
pKESMS78 PenvR lacZ in pKES268 cloned with OA526/OA527 
pKESMS79 leuO-S120D-His6 in pFDY157 cloned with S326/S400 
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a)
 The following abbreviations and genetic designations are used: MCS, multiple cloning site, rep
ts
, temperature 
sensitive origin of replication, aadA refers to spectinomycin resistance, cmR for chloramphenicol resistance, 
neo for kanamycin resistance (kanR), ampR for ampicillin resistance. DBD refers to the N-terminal DNA-binding 
domain of LeuO, from amino acid 1 to amino acid 101 of the protein. EBD refers to the C-terminal effector-
binding domain of LeuO, from amino acid 108 to amino acid 314 (end of protein). 
b)
 For cloning, PCR fragments were amplified with the indicated oligonucleotides. Vectors and PCR fragments 
were digested with restriction enzymes, gel purified and cloned. All cloned plasmids were confirmed by PCR, 
restriction digestion, and sequencing of the cloned fragment. 
The LeuO mutant screen using either Pcas-lacZ (T1281, T1610) or Pbgl-lacZ (T568) as reporter, LeuO mutants 
marked with (2x) and (3x) were isolated two or three times independently (from independent PCR runs), the 
asterisk (*) marks mutations that were isolated independently but with different secondary mutation or 
synonymous substitution. 
 
Table 4: Oligonucleotides 
oligo sequence
a)
 application/target 
S93 CCGGGCCGACAACAAAGTCA analysis of attB integration 
S95 CATATGGGGATTGGTGGCGA analysis of attB integration 
S118 TGCGGGCCTCTTCGCTATTA analysis of attB integration 
S164 GAGCAGGGGAATTGATCCGGTGGA analysis of attB integration 
S326 aagaattcggatccGTGTGACAGTGGAGTTAAGTATGCCAG leuO cloning 
S328 ccctgcagctagcTGACCTATTCTGCAATCAGTTAGCG leuO cloning 
S400 tactgcagctagcttaatgatgatgatgatgatgGCGTTTGCAAATTGAGACTAATT
GC 
leuO cloning 
T334 TGGCGAAGTAATCGCAACATCC analysis of attB integration 
T645 aggtggatccTGACCTATTCTGCAATCAGTTAGCG leuO cloning in pKETS24 
T734 gcaggtcgacCCAGAGACAGTTCAAAAAAGAGTCAGTC PuspG 
T735 gcagtctagaATACATAACCCTTTCTCCCTGTTAATCA PuspG 
T736 gcaggtcgacGTCATCCCTGCAAATCCCAAATAAC Pcas 
T737 gcagtctagaATATGCTCCGACATTTCTCCTGC Pcas 
T738 gcaggtcgacCAGTACTTTGCTTTTCATTGAATAAATCCT PmicC 
T739 gcagtctagaGTGACAATAAAGGCATATAACCCGC PmicC 
T740 gcaggtcgacGTGACAATAAAGGCATATAACCCGC PompN  
T741 gcagtctagaCAGTACTTTGCTTTTCATTGAATAAATCCT PompN  
T792 CGTGTATTTCATCTTTGTGTTTGCgatCCGTTAGACAGCATTCTGAC leuO-S120D mutagenesis 
T793 GTATTTCATCTTTGTGTTTGCAGCgatTTAGACAGCATTCTGACCTCG leuO-P121D mutagenesis 
T794 ATCTTTGTGTTTGCAGCCCGgaaGACAGCATTCTGACCTCGC leuO-L122E mutagenesis 
T795 TTTGCAGCCCGTTAGACAGCgaaCTGACCTCGCAGATTTATAATCAC leuO-I125E mutagenesis 
T796 TCAGGAAACGGAGTTTGTGATTAGTgaaGAAGACTTCCATCGTCCTG leuO-Y168E mutagenesis 
T800 CGGCGGTTTCGCTCGATCGTgaaGCGTCATTTAGTCAACCTTG leuO-F219E mutagenesis 
T801 GCGTATCAGGGCATGGCAgaaATGAGCGTACTTAGCGTGG leuO-M243E mutagenesis 
T802 ATTGCGCCGCGTTGGgaaGCTGAAGAGTTCGCTGA leuO-L263E mutagenesis 
T803 gaccgctagcGTGTGACAGTGGAGTTAAGTATGCCAG leuO cloning in pKETS24 
T806 gcaggtcgacCGACACCCGTTGTTAACTTATCCAT PnmpC 
T807 gtcatctagaGCCACTGTTAATTTTTTCATCGTGAG PnmpC 
T808 gtcagtcgac CGAGAAGTTTCTGCTGCAATAATAAGA PsdiA 
T809 gcagtctaga GCTGAAAAAATCCTTATCCTGCATAGTAAA PsdiA 
T810 gcaggtcgac CTTCTCTTCTCGTAGACATAGAACTTCCTG PgspC 
T811 gcagtctaga AACGTAGTGTGGGCACGATGTATGT PgspC 
T912 GCTGGTGGCACTGGGTAGTTGTTA analysis of attB integration 
T945 AGAATGCTGTCttcCGGGCTGCAAACACAAAGAT leuO-L122E mutagenesis 
T967 AAATCCGCGCCTGAGCGCAAAAGGAATATAAAAATGACCACGAAGgtgt
aggctggagctgcttcg 
ilvE deletion 
T968 TTGTATTTATTGATTAACTTGATCTAACCAGCCCCATTTATCTTCcatatgaa
tatcctccttagttcctattcc 
ilvE deletion 
T978 TTGTGTTTGCgcgCCGTTAGACAGCATTCTGACCTC leuO-S120A mutagenesis 
T979 GTCTAACGGcgcGCAAACACAAAGATGAAATACACGT leuO-S120A mutagenesis 
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oligo sequence
a)
 application/target 
T980 CATGGCAATGgcgAGCGTACTTAGCGTGGTGTCG leuO-M244A mutagenesis 
T981 AAGTACGCTcgcCATTGCCATGCCCTGATACG leuO-M244A mutagenesis 
T984 TCAGGGCATGGCAATGgcgAGCGTACTTAGCGTGGTGTCG leuO-M244A mutagenesis 
T994 AGTTAAGTATGCCAGAGGTACAAACAGATCATCCAGAGACGGCGGcgaa
ccccagagtcccgc 
leuO deletion 
T995 GACCTATTCTGCAATCAGTTAGCGTTTGCAAATTGAGACTAATTGCTCcgt
catcgccattaattcactgat 
leuO deletion 
T996 AGTTAAGTATGCCAGAGGTACAAACAGATC leuO cloning 
T997 GACCTATTCTGCAATCAGTTAGCGTT leuO cloning 
OA001 tcacCATATGCAGTTTAAGGTTTACACCTATAAAAGAG ccdB cloning 
OA002 tcacGGATCCACTGGCTGTGTATAAGGGAGCCTG ccdB cloning 
OA005 tcaccatATGCCAGAGGTACAAACAGATCATCC leuO cloning in pET-22b(+) 
OA006 tcaccatatgGCGAGCAGTGAACGTGTATTTCAT leuO-EBD cloning in pET-22b(+) 
OA008 tcacctcgagGCGTTTGCAAATTGAGACTAATTGC leuO cloning in pET-22b(+) 
OA182 TTATATGTTTTGCGATTTTTTTTGATATTG PleuO EMSA fragment 
OA183 ATTTAATGCATTAATTCTTAACATTAATTGATCA PleuO EMSA fragment 
OA184 GTAATTAATTCAATAATCACATTCACTGCAA Pcas EMSA fragment 
OA185 CATCTTAATATATGTATAGGTTAATTGTATTAAACCAA Pcas EMSA fragment 
OA186 CAAGTCTTCATTAgctCAGAACACTGAACATCAGCTGCG leuO-N150A mutagenesis 
OA187 GTTCAGTGTTCTGagcTAATGAAGACTTGAACATAACATGTATATTTGG leuO-N150A mutagenesis 
OA188 AGTCTTCATTAAATgcgAACACTGAACATCAGCTGCGTTATC leuO-Q151A mutagenesis 
OA189 TTCAGTGTTcgcATTTAATGAAGACTTGAACATAACATGTATATTT leuO-Q151A mutagenesis 
OA190 TCATTAAATCAGgccACTGAACATCAGCTGCGTTATCAG leuO-N152A mutagenesis 
OA191 ATGTTCAGTggcCTGATTTAATGAAGACTTGAACATAACATGTA leuO-N152A mutagenesis 
OA192 GAACACTGAAgctCAGCTGCGTTATCAGGAAACG leuO-H155A mutagenesis 
OA193 GATAACGCAGCTGagcTTCAGTGTTCTGATTTAATGAAGACTTGA leuO-H155A mutagenesis 
OA194 AACACTGAACATgcgCTGCGTTATCAGGAAACGGAGTT leuO-Q156A mutagenesis 
OA195 GATAACGCAGcgcATGTTCAGTGTTCTGATTTAATGAAGACTT leuO-Q156A mutagenesis 
OA196 AACATCAGCTGgctTATCAGGAAACGGAGTTTGTGATTAGTT leuO-R158A mutagenesis 
OA197 TTCCTGATAagcCAGCTGATGTTCAGTGTTCTGATTTAAT leuO-R158A mutagenesis 
OA198 TTATGAAGACTTCgctCGTCCTGAATTTACCAGCGTACC leuO-H172A mutagenesis 
OA199 ATTCAGGACGagcGAAGTCTTCATAACTAATCACAAACTCCG leuO-H172A mutagenesis 
OA200 TGAAGACTTCCATgctCCTGAATTTACCAGCGTACCATTATT leuO-R173A mutagenesis 
OA201 GTAAATTCAGGagcATGGAAGTCTTCATAACTAATCACAAACTC leuO-R173A mutagenesis 
OA202 GTTACTGAAAgctGATGTTTATAACGAACAACATGCGG leuO-H204A mutagenesis 
OA203 TTCGTTATAAACATCagcTTTCAGTAACGGGCCCTTAATTG leuO-H204A mutagenesis 
OA204 CGCTCGATgctTTCGCGTCATTTAGTCAACCTTG leuO-R218A mutagenesis 
OA205 TAAATGACGCGAAagcATCGAGCGAAACCGCCG leuO-R218A mutagenesis 
OA206 AGTCAACCTgcgTATGACACGGTAGATAAGCAAGCCA leuO-W226A mutagenesis 
OA207 CTACCGTGTCATAcgcAGGTTGACTAAATGACGCGAAACG leuO-W226A mutagenesis 
OA208 CGGTAGATgcgCAAGCCAGTATCGCGTATCAGG leuO-K232A mutagenesis 
OA209 GCGATACTGGCTTGcgcATCTACCGTGTCATACCAAGGTTGAC leuO-K232A mutagenesis 
OA210 CAAGTCTTCATTAgagCAGAACACTGAACATCAGCTGCG leuO-N150E mutagenesis 
OA211 GTTCAGTGTTCTGctcTAATGAAGACTTGAACATAACATGTATATTTGG leuO-N150E mutagenesis 
OA212 AGTCTTCATTAAATgagAACACTGAACATCAGCTGCGTTATC leuO-Q151E mutagenesis 
OA213 CTGATGTTCAGTGTTctcATTTAATGAAGACTTGAACATAACATGTATATT
TG 
leuO-Q151E mutagenesis 
OA214 TTCATTAAATCAGgagACTGAACATCAGCTGCGTTATCAG leuO-N152E mutagenesis 
OA215 TGATGTTCAGTctcCTGATTTAATGAAGACTTGAACATAACATGT leuO-N152E mutagenesis 
OA216 CAGAACACTGAAgagCAGCTGCGTTATCAGGAAACG leuO-H155E mutagenesis 
OA217 AACGCAGCTGctcTTCAGTGTTCTGATTTAATGAAGACTTGA leuO-H155E mutagenesis 
OA218 TCAGAACACTGAACATgagCTGCGTTATCAGGAAACGGAGT leuO-Q156E mutagenesis 
OA219 ATAACGCAGctcATGTTCAGTGTTCTGATTTAATGAAGACTT leuO-Q156E mutagenesis 
OA220 TGAACATCAGCTGgagTATCAGGAAACGGAGTTTGTGATTAGT leuO-R158E mutagenesis 
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OA221 GTTTCCTGATActcCAGCTGATGTTCAGTGTTCTGATTTAAT leuO-R158E mutagenesis 
OA222 TATGAAGACTTCgagCGTCCTGAATTTACCAGCGTACC leuO-H172E mutagenesis 
OA223 AATTCAGGACGctcGAAGTCTTCATAACTAATCACAAACTCCG leuO-H172E mutagenesis 
OA224 TGAAGACTTCCATgagCCTGAATTTACCAGCGTACCATTATT leuO-R173E mutagenesis 
OA225 GTAAATTCAGGctcATGGAAGTCTTCATAACTAATCACAAACTC leuO-R173E mutagenesis 
OA226 CCGTTACTGAAAgagGATGTTTATAACGAACAACATGCGG leuO-H204E mutagenesis 
OA227 GTTCGTTATAAACATCctcTTTCAGTAACGGGCCCTTAATTG leuO-H204E mutagenesis 
OA228 CGCTCGATgagTTCGCGTCATTTAGTCAACCTTG leuO-R218E mutagenesis 
OA229 AATGACGCGAActcATCGAGCGAAACCGCCG leuO-R218E mutagenesis 
OA230 ATTTAGTCAACCTgagTATGACACGGTAGATAAGCAAGCCA leuO-W226E mutagenesis 
OA231 CTACCGTGTCATActcAGGTTGACTAAATGACGCGAAACG leuO-W226E mutagenesis 
OA232 GACACGGTAGATgagCAAGCCAGTATCGCGTATCAGG leuO-K232E mutagenesis 
OA233 TACTGGCTTGctcATCTACCGTGTCATACCAAGGTTGAC leuO-K232E mutagenesis 
OA282 ATTATTAAATAAGCACATTTAATCCATTTTGTAG PleuO EMSA fragment 
OA283 TGTTGCGAAAACAATCTAATCATAACTAC PleuO EMSA fragment 
OA284 ACTTTTAGTTATAATAATTACCATGAATTTTATTACATAA Pcas EMSA fragment 
OA285 ATTTCCCGGTATGAGATTTTATATTCAC Pcas EMSA fragment 
OA286 AACTATCACATGAATATTATCATCATAATGAATTT PyjjQ EMSA fragment 
OA287 ACGTGCCCGGTTATCTATTATCCT PyjjQ EMSA fragment 
OA288 GCGGGAAGGGATATCATTTAATTATA PyjjQ EMSA fragment 
OA289 ACATTAAGTTGTTAGGAATACTTAATGAAAAACAG PyjjQ EMSA fragment 
OA290 AGTGAATGCTAAGGATAATTTATTCGCT PyjjQ EMSA fragment 
OA291 GGTTTATTCAGGATATTCATTCCTTAAATG PyjjQ EMSA fragment 
OA432 GTATTTCATCTTgatGTTTGCAGCCCGTTAGACAGCA leuO-C117D mutagenesis 
OA433 GGCTGCAAACatcAAGATGAAATACACGTTCACTGCTCG leuO-C117D mutagenesis 
OA434 GTATTTCATCTTagcGTTTGCAGCCCGTTAGACAGCA leuO-C117S mutagenesis 
OA435 GGCTGCAAACgctAAGATGAAATACACGTTCACTGCTCG leuO-C117S mutagenesis 
OA436 CATCTTTGTGTTgatAGCCCGTTAGACAGCATTCTGACC leuO-C119D mutagenesis 
OA437 TGTCTAACGGGCTatcAACACAAAGATGAAATACACGTTCACTGC leuO-C119D mutagenesis 
OA438 CATCTTTGTGTTagcAGCCCGTTAGACAGCATTCTGACC leuO-C119S mutagenesis 
OA439 TGTCTAACGGGCTgctAACACAAAGATGAAATACACGTTCACTGC leuO-C119S mutagenesis 
OA440 tacggctagcttaAGGCAATTCATTTTGTACTAGTTGCA leuO-DBD cloning 
OA473 TACGTCGGCACACTTCCGTTAT DNase I footprint Fc, Fd 
OA474 CTGCATTTCTATACGTCGGCACACTT DNase I footprint Fa 
OA475 ATGCATTTCAAATCTGCAAGTTATTCGTT DNase I footprint Fb 
OA476 TTGAAATGCATGCATTATTGTCTTTAAAC DNase I footprint Fc 
OA477 CCTACTTAAGTAGGGAAGGTGCACAATG DNase I footprint Fa, Fb, Fd 
OA514 gcaggtcgacAATGAGTTCAGAGAGCCGCAAGA PyafT 
OA515 gcaggctagcACAAAGCTTTTTTGAATTCATAATTGGACACTCCCTCGCCT PyafT 
OA516 gcaggtcgacAAGGTAATTCATGGATGGTTGAACTATATC PybdO 
OA517 gcagtctagaTAAGTCGAACTTTTTCAAGTCGTAGAGATT PybdO 
OA518 gcaggtcgacTTGCGACTCCATGTCCATATAATTTAT PybeQ 
OA519 gcagtctagaGCAGCAACTTGACGTGAAAATCATTATC PybeQ 
OA520 gcaggtcgacGCAGCAACTTGACGTGAAAATCATTATC PybeR 
OA521 gcagtctagaTTGCGACTCCATGTCCATATAATTTAT PybeR 
OA522 gcaggtcgacTAATGGAGGTGTTATTGACTGCATGA PyghS 
OA523 gcagtctagaCATATTACGTTGATTCACGAAAAACCCGGCA PyghS 
OA524 gcaggtcgacCATATTACGTTGATTCACGAAAAACCCGGCA PyghT 
OA525 gcagtctagaTAATGGAGGTGTTATTGACTGCATGA PyghT 
OA526 gcaggtcgacCCTGGCATGTTTCGTCATTACTATTCCTCAA PenvR 
OA527 gcagtctagaAGCTTCGGCTTTGGTTCTTTTTGCCATGA PenvR 
OA528 gcaggtcgacAGCTTCGGCTTTGGTTCTTTTTGCCATGA PenvC 
OA529 gcagtctagaCCTGGCATGTTTCGTCATTACTATTCCTCAA PenvC 
OA530 gcaggtcgacGTGCGCCAGCGCAGCTAATTTCTCAGAATTATG PyjfI 
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Table 4: Oligonucleotides 
oligo sequence
a)
 application/target 
OA531 gcagtctagaTAGCGCCAACGGATTCCATGTCATA PyjfI 
OA576 Phos-agcttGCAGCAG adaptor pKES334 
OA577 Phos-ctagcTGCTGCA adaptor pKES334 
a)
 Nucleotides homologous to the indicated template are shown in capital letters, non-matching parts are 
shown in lower case letters, and sites for restriction endonucleases are underlined. 
 
4.4 CaCl2-competent cells and transformation 
For preparation of CaCl2-competent cells, 25 ml LB medium was inoculated with a fresh single colony 
and grown to OD600 of 0.3. Cultures were harvested on ice and pelleted by centrifugation at 4°C for 
10 min at 3000 rpm. The cell pellet was resuspended in 12.5 ml ice-cold 0.1 M CaCl2, incubated for 20 
min on ice and pelleted again by centrifugation. The cell pellet was resuspended in 1 ml 0.1 M CaCl2. 
Cells were used directly for transformation, or for long-term storage at -80°C, glycerol was added 
(15% final concentration) and incubated for 1 hour. For transformation 10 μl of a ligation or 1 to 
100 ng of plasmid DNA was prepared in 50 μl TEN-buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 50 mM 
NaCl), mixed with 100 μl of competent cells and incubated for 10 min on ice. The cells were 
incubated for exactly 2 min at 42°C (heat shock) and again for 10 min on ice. The cells were 
transferred to culture tubes with 1 ml LB medium added and incubated for 1 h at 37°C or appropriate 
temperature. 100 μl of the culture was plated on LB plates with appropriate antibiotics. 
4.5 Electrocompetent cells and electroporation 
For preparation of electrocompetent cells 50 ml SOB medium was inoculated from an overnight 
culture and grown to OD600 0.6. The culture was incubated on ice for 1 h and pelleted by 
centrifugation at 4°C for 15 min at 3000 rpm. The cells were resuspended in 50 ml ice-cold sterile 
H2O, pelleted by centrifugation and resuspended in 25 ml ice-cold sterile H2O. The cells were again 
pelleted and resuspended in 2 ml ice-cold 10% glycerol and finally the cell pellet was resuspended in 
200 µl ice-cold 10% glycerol. The cells were used directly for electroporation, or frozen at -80°C for 
long-term storage. For electroporation 1 μl of DNA (e.g. 100 ng PCR fragment for λ-Red 
recombineering) was mixed with 40 μl of electrocompetent cells. The samples were incubated for 
10 min on ice and transferred to a precooled electroporation cuvette (Bio-Rad). Electroporation was 
carried out with a Bio-Rad Gene Pulser with 1.8 kV for 3 ms. The cells were transferred to 1 ml SOC 
medium and incubated at 37°C for 1 hr. 100 μl of the culture was plated on LB plates with 
appropriate antibiotics. 
SOB medium (for 1 l): 20 g Bacto Tryptone, 5 g Bacto Yeast Extract, 5 g NaCl, 15 g Bacto Agar  
SOC medium: 19.8 ml of 20% glucose added to 1 l of SOB 
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4.6 Random mutagenesis screen 
The random mutagenesis screen was performed to identify LeuO mutants that are constitutively 
active. For mutagenesis the leuO gene fragment was amplified in 25 parallel reactions using a non-
proofreading Tag polymerase (Promega). In brief, leuO was amplified with oligos S326 and S328 and 
pKETS25 as a template. The leuO gene fragments were purified and digested with restriction 
endonucleases NheI and EcoRI, and ligated into pKESK22. Transformants of the Pcas-lacZ reporter 
strain (T1281 or T1610) with these ligations were plated on Tryptone X-Gal kanamycin indicator 
plates and screened for a Lac-positive phenotype. Clones with a Lac-positive phenotype were 
analyzed by sequencing. 
 
4.7 Site-directed mutagenesis by overlap PCR 
Site-directed mutagenesis was used for mutation of the leuO gene and carried out by a two step 
overlap PCR. In the first step, two PCRs were carried out from pKETS25 as a template. For 
amplification of PCR A the forward primer S326 and the reverse primer carrying the desired mutation 
was used (see Table 4). In PCR B the forward primer, carrying the desired mutation (corresponding to 
mutation in PCR A) and the reverse primer S328 was used. The DNA fragments from PCR A and B 
were gel purified and used as the template in the second step for PCR C with primer S326 and S328. 
The fragments were then digested with restriction endonucleases NheI and EcoRI and ligated into the 
vector pKESK22. DH5α cells were transformed with the ligation and the correct mutation was verified 
by PCR and sequencing. 
 
4.8 Chromosomal integration into attB sites 
Promoter lacZ fusions were integrated into the chromosomal λ attachment site attB, of derivates of 
the ΔlacZ strain (S4197) as described (Diederich et al., 1992, Dole et al., 2002). In brief, the target 
strain was transformed with the integrase-expressing helper plasmid pLDR8 and transformants were 
selected on LB kanamycin plates at 28°C. Overnight cultures of transformants were grown at 28°C 
and diluted twenty-fold and grown for 90 min at 37°C to induce integrase expression. The cultures 
were used to prepare chemically competent cells, as described above. Plasmids carrying the 
promoter lacZ fusion, the attP site and a spectinomycin resistance cassette were digested with 
BamHI. Fragments were purified by gel electrophoresis and 10 ng of the fragments self-ligated. 
Compentent cells were transformed with 10 μl of this ligation and selected on prewarmed LB 
spectinomycin plates at 42°C. At 42°C, the integrase promotes the recombination between attP and 
attB sites resulting in the integration of the lacZ promoter fusion into the chromosome, while 
simultanously the pLDR8 plasmid is cured at high temperature. The colonies were verified by PCR 
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analysis using primer pairs S93/S164 (analysis of attB/P’ site), S95/T912 (analysis of attP/B’ site), 
S95/S164 (exclusion of dimers), and T334/S118 (analysis of reporter construct) and were tested for 
kanamycin sensitivity (loss of pLDR8). 
 
4.9 Gene deletion and insertion using λ-Red mediated recombination 
Gene deletion of chromosomal genes was performed as described (Datsenko & Wanner, 2000). This 
method is based on homologous recombination between linear DNA fragments and the 
chromosomal locus mediated by the λ‐Red recombination system. In brief, the chromosomal gene 
sequence is replaced with a selectable antibiotic resistance gene (chloramphenicol or kanamycin) 
flanked by FRT sites (Flp Recombination Target). The linear DNA fragments are generated by PCR, 
using oligonucleotides with a 35 to 50 nucleotide homology to the target chromosomal locus and 
pKD3 (cmR) or pKD4 (kanR) as a template. Gel-purified PCR fragments (100 ng/µl in H2O) were 
electroporated into cells harbouring the helper plasmid pKD46 expressing λ‐Red recombinase. 
Electrocompetent cells were prepared from cultures grown at 28°C in SOB medium supplemented 
with 10 mM L‐arabinose for induction of λ‐Red recombinase. 
The recombinants were selected at 37°C on LB plates, supplemented with chloramphenicol or 
kanamycin. The insertion of the resistance cassette at the target gene location was confirmed by 
PCR. The loss of the helper plasmid was confirmed by ampicillin sensitivity. The FRT sites flanking the 
resistance cassette allow the deletion of the resistance gene by expressing the Flp recombinase from 
the helper plasmid pCP20. The respective strain was transformed with pCP20 and selected on LB amp 
plates at 28°C. Transformants were restreaked on LB plates and incubated at 42°C to induce 
expression of the Flp recombinase and loss of the plasmid. The loss of the antibiotic resistance 
casette was confirmed by PCR and antibiotic sensitivity of the clones. The loss of the plasmid pCP20 
was confirmed by antibiotic sensitivity of the clones to ampicillin. 
 
4.10 Chromosomal two-step mutagenesis using λ-Red mediated recombination 
For introducing point-mutations of leuO into the wild-type chromosomal background (BW30270) a 
two-step method based on the λ‐Red recombinase system, was carried out according to (Datsenko & 
Wanner, 2000) and (Kolmsee & Hengge, 2011). In a first step, the target gene is replaced by a DNA 
fragment encoding for kanamycin resistance and a ccdB toxin with a rhamnose-inducible promoter. 
In a second step the leuO::kanR-ccdB cassette is replaced by the mutated leuO (leuO-S120D, leuO-
M244T, leuO-S120D/M244T) using again the λ‐Red system and counter-selected on LB plates 
supplemented with 12 mM rhamnose. In brief, a fragment of plasmid pKILL45 (carrying the 
kanamycin resistance cassette and the ccdB gene under the control of rhaP3 was amplified by PCR 
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using oligonucleotides (T994/T995) that carry extensions homologous to leuO. The target strain was 
transformed with the helper plasmid pKD46 expressing λ‐Red recombinase and cells were made 
electrocompetent according to the protocol described above. The gel-purified PCR fragment was 
electroporated into the cells, and recombinants were selected on LB plates with kanamycin at 37°C. 
The insertion of the kanR-ccdB gene was confirmed by PCR and sequencing. For the second step, this 
intermediate strain was transformed with pKD46 and electrocompetent cells were prepared. PCR 
fragments of leuO, carrying the mutations (leuO-S120D, leuO-M244T, leuO-S120D/M244T) were 
amplified from plasmids (pKESL104, pKESL73 and pKESL107, respectively) using oligonucleotides 
T996 and T997. The intermediate strain leuO::kanR-ccdB was transformed with pKD46 and cells were 
made electrocompetent (chapter 4.5). The gel-purified PCR fragments carrying the leuO mutations 
were used for electroporation into the cells and recombinants were selected on LB plates with 
rhamnose at 37°C. The induction of toxin ccdB with rhamnose ensures the survival of recombinants 
carrying the leuO mutation and kills cells carrying the ccdB-kanR casette. The loss of the ccdB-kanR 
casette was analyzed by PCR and sequencing. In addition, sensitivity of cells to kanamycin was 
confirmed. 
 
4.11 Phage transduction 
The phage transduction method is based on the ability of phage T4GT7 to transfer DNA between 
bacteria (Wilson et al., 1979). In brief, for T4GT7-lysate 100 μl of an overnight culture of the donor 
strain was incubated with different concentrations of a wild-type T4GT7-lysate for 15 min. Then 1 ml 
of LB medium was added and the mixture was transferred to a culture tube with 3 ml T4-Topagar. 
The lysate-mix was poured on a fresh LB plate and incubated for 8 to 14 hours. Plates that showed a 
confluent lysis were used to isolate the phages by chloroform extraction. For transduction, 100 μl of 
an overnight culture of the recipient strain was incubated with different concentrations of the 
bacteriophage lysate for 15 min and plated on LB plates with appropriate antibiotics for selection. 
The transductants were restreaked at least four times to get rid of contaminating T4GT7 phages. The 
transfer of the allele (and other relevant loci) was verified by PCR with specific primers. 
 
4.12 Expression analysis 
For expression analyses of promoter lacZ fusions β-galactosidase assays were performed, as 
described (Miller, 1992). Briefly, exponential cultures were inoculated from a fresh overnight culture 
to an OD600 0.1 in LB medium that was supplemented with the specific antibiotic in case of 
transformants. Where indicated, IPTG was added for induction both to the overnight and the 
exponential culture to a final concentration of 1 mM. Cultures were grown at 37°C to OD600 0.5 and 
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then harvested on ice. The β-galactosidase assays were repeated at least three times from 
independent biological replicates. 
 
4.13 Protein purification of LeuO and LeuO mutants 
For purification of C-terminally histidine-tagged LeuOHis6, LeuO-S120DHis6 and LeuO-DBDHis6, 
expression strain BL21(DE3)C41 was transformed with plasmids carrying the respective encoding 
genes under the control of a T7 promoter (Table 3). Two liter cultures of LB medium with ampicillin 
were inoculated to an OD600 of 0.1 and grown at 37°C to OD600 of 0.6. At this point the protein 
expression was induced by adding IPTG to a final concentration of 200 µM and the cultures were 
grown for further 5 h at 28°C. The cultures were harvested and the bacteria pelleted by 
centrifugation. The cells were resuspended in resuspension buffer (20 mM Tris-HCl pH 8.0, 300 mM 
NaCl), and again pelleted for storage at -80°C. Lysate preparation was performed at 4°C; the cell 
pellets were resuspended in lysis buffer [4 ml/g of cells; 20 mM Tris-HCl pH 8.0, 300 mM NaCl, 
10 mM Imidazole, 20 µg/ml DNase I (5000 U/ml; New England Biolabs, USA)] and lysed by sonication 
(40% amplitude, 4 minutes with a 2 seconds pulse/ 2 seconds pause; Sonics Vibracell VCX750 High-
Volume Ultrasonic Cell Disrupter). The lysate was cleared by centrifugation (35.000 rpm, 45 min, Ti70 
rotor, Beckman Coulter XL70) and the supernatant was loaded onto 1 ml HisTrap HP column (GE 
Healthcare, Germany) using an ÄKTA fast protein liquid chromatography (FPLC) system (GE 
Healthcare, Germany). The column was washed with the same buffer (20 mM Tris-HCl pH 8.0, 
300 mM NaCl) with increasing imidazole concentrations (10 mM, 20 mM, 40 mM, and 60 mM), with 
each step equal to at least 10 column volumes. The proteins were eluted with 20 mM Tris-HCl pH 8.0, 
300 mM NaCl, 250 mM Imidazole, the 1 ml fractions were collected and analyzed by SDS-PAGE. The 
protein containing fractions were pooled and the buffer was exchanged with a PD-10 desalting 
column (GE Healthcare, Germany) to storage buffer (for LeuO-DBDHis6: 20 mM Tris-HCl pH 8.0, 
200 mM NaCl, 50 mM NDSB-256; for LeuOHis6 and LeuO-S120DHis6: 20 mM Tris-HCl pH 8.0, 500 mM 
NaCl, 1 mM DTT 150 mM NDSB-256). Protein concentrations were measured by Qubit Fluorometric 
Quantitation system (Invitrogen, Germany). Aliquots of the proteins were stored at -80°C. 
 
4.14 SDS-PAGE 
Purified proteins were analyzed by SDS polyacrylamide gel electrophoresis (SDS-PAGE), as described 
before (Ausubel, 2005). Protein samples were resuspended in 1x SDS-loading buffer [50 mM Tris-HCl 
(pH 6.8), 1.5% SDS, 5% glycerol, 0.05% bromophenol blue, 125 mM DTT] and boiled for 5 minutes at 
95°C and 10 μl were loaded on 12% SDS-polyacrylamide gels containing 0.005% TCE (2,2,2-
Trichloroethanol). Gels were run at 100 V and 40 mA for 20 min and at 150 V for approximately 1.5 
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hours. The gels were analyzed in a fast approach by detecting the flourescence of the protein bands, 
caused by the ultraviolet light-induced reaction of the the tryptophans in the protein with 
trihalocompounds of the TCE. In addition, the gels were stained with Coomassie Brilliant blue. 
 
4.15 Crystallization of LeuO-EBD and LeuO-S120D-EBD 
For crystallization, C-terminally histidine-tagged LeuO effector-binding domains LeuO-EBDHis6 and 
LeuO-S120D-EBDHis6 were purified as described above for the full-length LeuO protein. Immediately 
after NiNTA affinity chromatography, the protein containing fractions were pooled and concentrated 
to 2 mg/ml protein using Vivaspin 20 (10,000 MWCO; Sartorius, Germany). Then the proteins were 
subjected to size exclusion chromatography (Superdex 200 16/600; GE Healthcare, Germany) at 4°C 
in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM DTT, 150 mM NDSB-256 using an ÄKTA purifier FPLC 
(GE Healthcare, Germany). The eluted fractions were analyzed by SDS-PAGE, and fractions containing 
pure protein were pooled and concentrated to 12.5 mg/ml. 
Both proteins were crystallized using the sitting-drop vapor diffusion method. LeuO-S120D-EBDHis6 
protein (12.5 mg/ml) was mixed with precipitant in a ratio 2:1 to form 300 nl drops and incubated at 
20°C. Crystals grew in a condition containing 0.1 M Tris, 1.2 M Na/K tartrate pH 8.0. Crystals with 
dimensions of about 80 x 50 x 50 µm3 were cryoprotected in 0.1 M Tris, 1.2 M Na/K tartrate pH 8.0, 
30% sucrose and flash-cooled in liquid nitrogen. 
LeuO-EBDHis6 protein (12.5 mg/ml) was mixed with precipitant in a ratio 1:2 to form 300 nl drops and 
incubated at 20°C. Crystals grew in a condition containing 0.2 M Lithium sulfate, 0.1 M Bis-Tris 
pH 5.5, 25% polyethylene glycol 3350. Crystals with dimensions of 90 x 90 x 50 µm3 were 
cryoprotected in 0.2 M Lithium sulfate, 0.1 M Bis-Tris pH 5.5, 32% polyethylene glycol 3350 and flash-
cooled in liquid nitrogen.  
The X-ray data collection, the structure determination and refinement was done by Anna Montada, 
Dr. Magdalena Schacherl and Prof. Dr. Ulrich Baumann, from the Institute for Biochemistry, Cologne. 
 
4.16 Electrophoretic shift assay (EMSA) 
DNA fragments used for EMSA were amplified by PCR. The concentrations were determined by 
adsorption measurements using Nanodrop (Thermo scientific, Germany) or Qubit Fluorometric 
Quantitation system (Invitrogen, Germany) instruments and by comparison of band intensities in 
agarose gels. Binding of LeuO to the DNA fragments was carried out in a final volume of 10 µl using 
10 ng of the 80 bp fragments (final concentration 20 nM). All dilutions of proteins and DNA 
fragments were set up in binding buffer (20 mM Tris HCl pH 7.5, 100 mM KCl, 2 mM DTT, 10% 
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glycerol). Protein was added in the indicated concentrations and after protein addition the samples 
were incubated at 30°C for 20 minutes. Samples were loaded on 8% native polyacrylamide gels 
(acrylamide:bisacrylamide 29:1; in running buffer 44.5 mM Tris, 44.5 mM Boric acid, 1 mM EDTA 
pH 8.0). Gels were run at 200 V for 1 h at 4°C and then stained with ethidium bromide (0.5 µg/ml, in 
running buffer) for 20 minutes. 
 
4.17 DNase I footprinting 
DNase I footprinting was carried out as described (Gaugué et al., 2013), with minor modifications. 
Briefly, 75 pmol of the oligonucleotides were labeled with 75 µCi [γ-32P]ATP (3000 Ci/mmol, 
Hartmann Analytics, Germany) in the presence of 20 units of T4 polynucleotide kinase (Thermo 
Fischer Scientific, Germany) in 50 µl T4 polynucleotide kinase buffer for 30 minutes at 37°C. 
Unincorporated nucleotides were removed from the labeled oligonucleotides using illustra 
ProbeQuant G50 Micro columns (GE Healthcare, Germany) that were pre-buffered with PCR buffer. 
Then, DNA fragments were generated by standard PCR in 50 µl with GoTaq polymerase (Promega, 
Germany) using 20 pmol of the [32P]-labeled oligonucleotide and a non-labeled oligonucleotide as 
reverse primer. The DNA fragment was purified by agarose gel electrophoresis and eluted with a gel 
purification kit (Machery Nagel, Germany). The concentration of the eluted fragment was measured 
using a Qubit Fluorometric Quantitation system (Invitrogen, Germany), and the counts per minute 
(cpm) were determined by Cerenkov counting. For each footprint reaction 120000 cpm 
(approximately 40 ng DNA) were used. Binding reactions were carried out for 10 minutes at 30 °C in 
40 µl of binding buffer (25 mM HEPES pH 8.0, 100 mM potassium glutamate pH 8.0, 0.5 mg/ml BSA) 
with increasing concentration of the protein, wild-type LeuOHis6, LeuO DNA-binding domain (LeuO-
DBDHis6), and LeuO-S120DHis6. Then, 0.02 units (in 4 µl) of DNase I were added (Thermo Fischer 
Scientific, Germany; diluted 200-fold in 10 mM Tris-HCl pH 8.0, 10 mM MgCl2, 10 mM CaCl2, 125 mM 
KCl, 0.1 mM DTT). Samples were incubated for 60 sec at 30°C and DNase I digestion was stopped by 
adding 100 µl Tris-HCl phenol pH 8.0 and 200 µl stop buffer (0.5 M Na-acetate pH 5.0, 10 µg/ml 
herring sperm DNA (Ultra Pure, Thermo Fischer Scientific, Germany), 2.5 mM EDTA) followed by a 
phenol extraction and ethanol precipitation. The DNA was dried in vacuo and resuspended in 5 µl 
H2O, followed by addition of 6 µl loading dye (95% formamide, 0.025% SDS, 0.025% bromophenol 
blue, 0.025% xylene cyanol FF, 0.025% ethidium bromide, 0.5 mM EDTA). The samples were heated 
for 2 min at 90°C and loaded on a 6% denaturing sequencing gel (6% long ranger (Lonza by Biozym 
Scientific, Germany), 7 M urea, 72 mM Tris-HCl, 72 mM boric acid, 1.6 mM EDTA) next to a sanger 
sequencing ladder, which was generated using the labeled oligonucleotide and the T7 polymerase 
sequencing kit (USB corporation, USA). The gel was washed with 10% ethanol, 10% acetic acid, 
transferred to Whatman 3 MM paper and dried in a gel dryer. Imaging was carried out by exposure 
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to phosphor-imaging plates and scanning by a Typhoon 7000 imaging system (GE Healthcare, 
Germany). 
 
4.18 Identification of a consensus LeuO DNA-binding site 
The DNase I footprint of LeuO DNA-binding site II at the cas promoter region was screened by eye 
and a 19 bp palindromic sequence of two 7 bp half-sites separated by 5 bp was detected. A similar 
palindromic sequence was found within DNA-binding site LeuO I (Stratmann et al., 2012) of the leuO 
regulatory region. Then, two 33 bp sequences covering the palindromic motifs of LeuO site II at the 
cas locus and LeuO site I at the leuO locus (Figure 18A) were submitted to MEME Suite (Bailey & 
Elkan, 1994) to generate a motif, which was subsequently submitted to FIMO (Grant et al., 2011) to 
search the E. coli K 12 genome (substr MG1655 uid225) for putative LeuO DNA-binding sites. The 13 
sequences with top scores (33.3 - 20.6; see 1. score in Table 5) were filtered regarding their 
intergenic position as well as their identification in a microarray (Stratmann et al., 2012), and a 
genomic SELEX screening (Shimada et al., 2011). Six of the 13 putative LeuO binding sequences 
fulfilled all criteria (see Table 5). In a second motif analysis, 33 bp sequences covering the six putative 
LeuO binding sites were submitted to MEME Suite to generate a less stringent motif (Figure 18B). 
When this motif was submitted to FIMO to search the E. coli K12 MG1655 genome for putative LeuO 
sites 37 LeuO DNA-binding sequences with the best motif scores (cut off value 14.0; see 2. score in 
Table 5) were identified. These were compared with previous microarray and SELEX data (Stratmann 
et al., 2012, Shimada et al., 2011), which yielded a striking correlation (see Table 5). A similar motif 
was obtained with less stringent conditions of filtering the initial 13 sequences. 
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Table 5: LeuO DNA-binding sites
a)
  
     flanking gene  flanking gene   
center
a
 str.
b
 matched sequence First 
scr.
c
 
2nd 
scr.
d
 
 genome position MA
e
   genome position MA
e
 SL
f
 function
g
 
4410096 + ATATTCATTTTATTAATAT 20.8 32.3 rlmB 4409275 -> 4410006   yjfI 4410133 -> 4410534 38.7 53.8 yjfI: conserved protein 
676686 + ATATTCATTTAATGAATAT 21.7 31.6 ybeQ 675570 <- 676547 43.0  ybeR 676711 -> 677418 20.1 9.5 ybeQ: conserved protein, ybeR: predicted polypeptide 
84024 + ATATTGATTTGGTGAATAT 33.3 31.1 leuL 83622 <- 83708 nd  leuO 84368 -> 85312 nd 14.7 leuO: LysR-type transcription regulator 
2884429 + ATATTCATACTGTGAATAT 33.3 30.4 casA 2882630 <- 2884138 65.4  cas3 2884553 <- 2887219 16.3 77.2 cas: CRISPR associated, bacterial defense system 
3134088 - ATATTTATTTGGTTAATAT 21.7 30.2 yghS 3133244 <- 3133957 28.0  yghT 3134131 -> 3134823 12.4 54.7 yghS, yghT: putative proteins with nucleoside triphosphate 
hydrolase domain 
3360901 - ATATTCATATTTTGTATAT 20.7 28.9 gltD 3359198 -> 3360616   gltF 3361176 -> 3361940 56.1 66.8 gltF: periplasmic protein 
2388299 + ATATTGATTTGGTCAATAT 27.0 23.8 yfbN 2387710 <- 2388426   yfbO 2388635 -> 2389057 9.3 14.4 yfbO: putative protein 
4591516 + ATATTTATATTGTGAATAA 21.7 22.9 yjiY 4589129 <- 4591279   tsr 4591657 -> 4593312  37.3 yjiY: inner membrane protein - putative transporter, 
tsr: methyl-accepting chemotaxis protein - serine-sensing 
2899081 - ATATTGATATTGAGAATAT 27.0 22.8 ygcS 2896533 <- 2897870   ygcU 2897964 <- 2899418   intragenic 
2099760 + ATATTTATTAAGTTAATAT  21.6 ugd 2098447 <- 2099613   gnd 2099862 <- 2101268   ugd: UDP-glucose 6-dehydrogenase 
1546229 + AAATTTATTTTTTTAATAT  21.4 yddL 1545738 <- 1546028   yddG 1546288 <- 1547169   yddL: putative lipoprotein 
234112 - ATATTGATTTAATTAATGT  20.8 mltD 232597 <- 233955   gloB 234027 <- 234782   mltD: membrane-bound lytic murein transglycosylase D 
3799266 + ATCTTGATTTTGTTTATAT  20.6 waaU 3798239 <- 3799312   waaZ 3799345 <- 3800196   intragenic 
1990189 - AGATTCACTTTGTGAATAT 20.7 17.9 yecH 1989251 <- 1989490   tyrP 1989681 -> 1990892   intragenic 
3136570 - ATATTTATTCATTTCATAT  17.8 pitB 3134872 <- 3136371 31.9  gss 3136663 <- 3138522  51.8 pitB: H+ symporter 
3770144 - ATATTCATTATGTTAATAA  17.2 yibV 3769345 -> 3769680   yibU 3769948 -> 3770146  7.3 intragenic 
1349241 + ATATTCATTTGATGAATCC  16.7 rnb 1346978 <- 1348912   yciW 1348980 <- 1350107   rnb: exoribonuclease II 
3412572 + TTATTCATTTCGTGTATAT  16.6 yhdJ 3411653 -> 3412537   yhdU 3412621 -> 3412800   yhdU: hypothetical protein 
237216 - ACATTCATTTAATCAATAT  16.4 aspV 236931 -> 237007   yafT 237335 -> 238120 7.8 5.9 yafT: predicted lipoprotein, putative aminopeptidase 
729459 - ATATATATTTCATGAATAT  16.4 ybfA 729134 -> 729340   rhsC 729583 -> 733776  4.0 rhsC: RhsC protein in rhs element 
3267484 + ACATTTATTTTATCAATAT  16.0 tdcA 3266127 <- 3267065   tdcR 3267380 -> 3267598  12.6 tdcA: LysR-type transcription regulator of metabolism during 
anaerobiosis 
578981 + AATTTCATATTGTTAATAT  15.9 borD 578600 <- 578893   ybcV 579184 <- 579594   borD (ybcU): lipoprotein bor homolog from lambdoid prophage DLP12 
1371792 - ATATTTACATGCTGAATAT  15.4 ycjM 1370216 -> 1371895   ycjN 1371909 -> 1373201   ycjN: putative periplasmic binding protein ABC family 
157242 - TTATTTATATTGCGAATAT  15.0 yadN 156299 <- 156883 13.6  folK 157253 <- 157732  7.2 yadN: cryptic fimbrial shaft protein 
576887 - ACATTGATTAGATGAATAT  15.0 nmpC 575758 <- 576825 -12.2  essD 577398 -> 577613  8.3 nmpC: general bacterial porin 
2884273 + ATATTCATTGGTTTAATAC  15.0 casA 2882630 <- 2884138 65.4  cas3 2884553 <- 2887219 16.3 77.2 cas: CRISPR associated 
1872765 - AGATTGTTTTTGTTAATAT  14.9 dgcJ 1872041 -> 1873531   yeaK 1873574 -> 1874077   yeaK: mischarged aminoacyl-tRNA deacylase 
3413622 - ATATTGATGTAGTGAATGT  14.9 envR 3412803 <- 3413465 48.3  envC 3413864 -> 3415021 21.0 81.3 envR (acrS): DNA-binding transcriptional repressor, envC (acrE): 
lipoprotein, drug efflux pump 
3772124 + ATATTTATGTGATTGATAT  14.7 yibI 3771382 <- 3771744   mtlA 3772281 -> 3774194   mtlA: mannitol-specific PTS enzyme II 
4004830 - TTATTGATAAGGTGAATAT 21.6 14.6 yigI 4004230 <- 4004697   pldA 4004862 -> 4005731 -4.8  yigI: putative thioesterase, pldA: outer membrane phospholipase 
637660 - ACATTGATTAAGTGAATAT  14.6 ybdO 636716 <- 637618 23.0  dsbG 637827 <- 638573  48.3 putative LysR-type transcription regulator, unknown function 
2575953 - ATATTCATGCGTTGCATAT  14.2 eutS 2575470 <- 2575805   maeB 2576098 <- 2578377   eutS: predicted structural protein, ethanolamine utilization 
3793735 - GTATACATTCTATTAATAT  14.1 htrL 3792826 <- 3793683   rfaD 3793987 -> 3794919  6.7 htrL (yibB): unknown; rfaD (waaD): LPS biosynthesis 
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Table 5: LeuO DNA-binding sites
a)
  
     flanking gene  flanking gene   
center
a
 str.
b
 matched sequence First 
scr.
c
 
2nd 
scr.
d
 
 genome position MA
e
   genome position MA
e
 SL
f
 function
g
 
156276 + ATATTCATTCAATCAATTT  14.0 yadV 155461 <- 156201   yadN 156299 <- 156883 13.6  yadV: cryptic pilin chaperone 
3288596 - ATATTCAGTTGGGTTATAT  14.0 yraI 3288090 -> 3288785   yraJ 3288814 -> 3291330   yraJ: putative fimbrial usher protein 
3640765 - ATATTGATGCGGTGAATAG 21.6 13.5 uspA 3640111 -> 3640545   dtpB 3640862 -> 3642331 -12.2  dtpB: dipeptide/tripeptide: H+ symporter 
3302287 + ATATTGCTTCGGTGAAAAT 20.6 12.9 yhbU 3301485 -> 3302480   yhbV 3302489 -> 3303367   yhbV: putative peptidase 
a)
 The center refers to the genome position of the matching motif sequence. 
b)
 refers to the DNA strand. 
c)
 The score refers to the motif score identified with FIMO (Grant et al., 2011); the regulation of the target in the microarray (MA) (Stratmann et al., 2012) and the binding by 
LeuO in SELEX (SL) (Shimada et al., 2011). The first motif score (First score) was obtained by submitting the motif depicted in the top panel of Figure 6 to FIMO to search the E. 
coli K 12 genome for putative LeuO DNA-binding sites. The 13 sequences displayed scores of 33.3 to 20.6 regarding the sequence identity to the given motif. In a second motif 
analysis (2nd score; cut off value 14.0) the LeuO binding motif depicted in the bottom panel of Figure 6 was submitted to FIMO, identifying the 37 putative LeuO sites shown 
here.  
d)
 The second score refers to the second motif analysis. 
e)
 Targets were identified in a microarray transcriptome analysis and the given values refer to the fold change regulation (Stratmann et al., 2012). 
f)
 Targets were identified by genome scale SELEX screening and the given values refer to the peak height (Shimada et al., 2011). 
g)
 Descriptions of protein functions were taken from the EcoCyc Database (Karp et al., 2014). 
 
 
A) MEME_1 
>84024  TTTTTTGATATTGATTTGGTGAATATTATTGAT 
>2884429 ACATAAAATATTCATACTGTGAATATAAAATCT 
 
B) MEME_2  
>84024  TTTTTTGATATTGATTTGGTGAATATTATTGAT 
>2884429 ACATAAAATATTCATACTGTGAATATAAAATCT 
>676686  GCGGCTAATATTCATTTAATGAATATTTAAGGA 
>3134088 TAAAAACATATTAACCAAATAAATATTTTTAAT 
>4410096 ATTGCAAATATTCATTTTATTAATATTTAAACT 
>3360901 GATATTAATATACAAAATATGAATATAAAAAAC 
 
Figure 18: FASTA files used for motif generation  
The motif was generated using MEME Suite (Bailey & Elkan, 1994). 
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